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  Cholesterol	   is	  an	  essential	  structural	  component	  of	  cells.	   In	  recent	  years,	  many	  studies	  have	  investigated	  its	  biochemical	  and	  biophysical	  properties,	  its	  metabolism	  in	  cells	  and	  throughout	   the	   body,	   as	   well	   as	   its	   pathogenic	   roles	   in	   diseases.	   Here	   we	   aimed	   to	  further	   explore	   the	   metabolic	   fate	   of	   cholesterol,	   as	   well	   as	   its	   precursors	   and	  metabolites	   from	   enzymatic	   perspectives.	   The	   three	   studies	   included	   in	   this	   thesis	  focused	   on	   lysosomal	   acid	   lipase	   (LAL),	   24-­‐dehydrocholesterol	   reductase	   (DHCR24),	  and	   amyloid	   precursor	   protein	   (APP).	   LAL	   hydrolyzes	   cholesteryl	   esters	   (CE)	   and	  generates	  free	  cholesterol	  (FC).	  DHCR24	  converts	  desmosterol	  to	  cholesterol	  in	  the	  last	  step	   of	   the	   Bloch	   pathway.	   APP	   is	   the	   precursor	   of	   the	   pathogenic	   amyloid	   β	   (Aβ)	  peptide	  for	  Alzheimer’s	  disease	  (AD),	  and	  is	  implicated	  in	  the	  cholesterol	  metabolism.	  	  
 We	  characterized	  the	  LAL-­‐mediated	  degradation	  of	  lipoprotein-­‐derived	  steroid	  esters	  in	  mammalian	  cells	  (I).	  Although	  the	  cellular	  metabolism	  of	  low-­‐density	  lipoprotein	  (LDL)-­‐carried	  CE	  is	  well	  studied,	  the	  pathway	  for	  LDL-­‐borne	  steroid	  esters	  is	  less	  well	  known.	  We	   investigated	   the	   cellular	   uptake	   of	   dehydroepiandrosterone-­‐fatty	   acyl	   ester-­‐LDL	  (DHEA-­‐FAE-­‐LDL)	   and	   its	   hydrolyzed	   metabolite	   pools	   in	   cells	   and	   in	   conditioned	  medium.	   We	   also	   compared	   the	   efficacy	   of	   DHEA-­‐FAE	   hydrolysis	   with	   that	   of	  cholesterol-­‐FAE	   in	  HeLa	  cells	   and	   fibroblasts.	  Our	   results	   showed	   that	  DHEA-­‐FAE-­‐LDL	  could	  be	   taken	  up	  by	   the	  LDL	  receptor	  (LDLr),	  after	  which	  DHEA-­‐FAE	  was	  hydrolyzed	  partially	   by	   LAL	   and	   converted	   into	   two	   major	   metabolites,	   5α-­‐androstanedione	   and	  androstenedione.	  	  We	   addressed	   the	   potential	   functions	   of	   desmosterol,	   an	   intermediate	   precursor	   of	  cholesterol,	  during	  brain	  development	  (II).	   In	   the	  central	  nervous	  system	  (CNS),	  sterol	  balance	   is	   largely	   independent	   of	   peripheral	   circulating	   sterols	   and	   has	   its	   own	  regulatory	   network.	   Desmosterol	   transiently	   accumulates	   in	   the	   developing	   brain	   of	  mammalian	   species;	   however,	   no	   causal	   explanation	   has	   been	   established	   and	   few	  consequent	   effects	   have	   been	   identified.	   Based	   on	   the	   literature	   and	   our	   own	  experimental	   findings,	   we	   proposed	   hypotheses	   for	   the	   cause	   of	   desmosterol	  accumulation	  and	  provided	  evidence	  for	  desmosterol	  regulation	  in	  the	  developing	  brain	  by	   progesterone.	   Furthermore,	   we	   investigated	   the	   possible	   roles	   of	   accumulating	  desmosterol	   in	   favoring	   brain	   development	   –	   desmosterol	   promotes	   sterol	   secretion	  from	  astrocytes	  and	  maintains	  an	  ample	  supply	  of	  active	  sterols	  in	  the	  developing	  brain.	  	  We	   investigated	   cholesterol	   metabolism	   regulation	   by	   APP	   in	   mammalian	   cells	   (III).	  Although	   APP	   has	   been	   extensively	   studied	   as	   a	   pathological	   factor	   in	   Alzheimer’s	  disease	  (AD),	  the	  ubiquity	  of	  APP	  expression	  in	  various	  tissues	  and	  the	  proposed	  trophic	  effects	   of	   APP	   on	   nerve	   growth	   suggest	   a	   physiological	   role	   of	   APP.	   In	   this	   study,	  we	  analyzed	   cholesterol	   biosynthesis	   and	   uptake	   regulation	   by	   APP	   and	   its	   proteolysis	  fragments,	   as	  well	   as	   amyloid	   precursor-­‐like	   protein	   2	   (APLP2),	   and	   found	   that	   these	  regulations	  were	  mediated	   via	   sterol	   regulatory	   element-­‐binding	   protein	   2	   (SRBEP2),	  the	  master	   protein	   that	   governs	   cholesterol	   homeostasis	   by	   initiating	   transcription	   of	  sterol-­‐related	  genes.	   In	   several	   cell	   types	   (human	  astrocytic	  and	  hepatocytic	   cells,	   and	  human	  primary	  fibroblasts),	  we	  showed	  that	  two	  APP	  ectodomains,	  APPsα	  and	  APPsβ,	  acted	   opposingly	   in	   cholesterol	   synthesis	   regulation	   depending	   on	   the	   APP	   α-­‐	   vs.	   β-­‐cleavage,	  via	  SREBP2.	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1.	  Cholesterol	  	  Cholesterol	  is	  an	  essential	  building	  block	  of	  the	  cell	  membrane	  and	  maintains	  important	  cellular	   functions.	   The	  molecular	   structure	   of	   cholesterol	   determines	   the	   rigidity	   and	  stiffness	  of	  lipid	  bilayers	  (Figure	  1)	  and	  directly	  affects	  biological	  events	  across	  the	  cell	  membrane,	   e.g.	   permeabilization	   of	   exogenous	   molecules	   and	   signal	   transduction.	  Deregulation	  of	  cholesterol	  results	  in	  multiple	  diseases	  spanning	  from	  atherosclerosis	  to	  developmental	  malformations.	  Therefore,	   cholesterol	   content	   and	  distribution	  need	   to	  be	  well	  maintained	  at	  both	  the	  cellular	  and	  whole-­‐body	  levels.	  	  	  
Figure	  1.	  Molecular	  structure	  of	  cholesterol.	  	  
	  
1.1	  Whole-­‐body	  cholesterol	  metabolism	  	  	  
1.1.1	  Cholesterol	  absorption	  	  Body	  cholesterol	  can	  be	  absorbed	  from	  the	  diet	  by	  the	  intestine.	  Niemann-­‐Pick	  C1-­‐like	  1	  (NPC1L1)	  protein	  is	  a	  crucial	  mediator	  in	  intestinal	  cholesterol	  absorption	  (Altmann	  et	  al.,	   2004).	  NPC1L1	  mRNA	   is	   expressed	  at	   low	   levels	   and	  mainly	   in	   the	   small	   intestine.	  NPC1L1	   is	   a	   transmembrane	  protein	   containing	  a	   sterol-­‐sensing	  domain,	   expressed	   in	  the	   brush-­‐border	  membranes	   of	   proximal	   enterocytes.	   Individuals	   with	   heterozygous	  nonsynonymous	  NPC1L1	  variation	  have	  a	  presumably	  50%	  reduction	   in	   sterol	  uptake	  and	  9%	  reduction	   in	  plasma	   low-­‐density	   lipoprotein	   (LDL)-­‐cholesterol	   (Ramirez	  et	  al.,	  2011).	   A	   cholesterol-­‐lowering	   drug,	   ezetimibe,	   functions	   as	   a	   cholesterol	   absorption	  inhibitor	  by	  targeting	  NPC1L1	  (Altmann	  et	  al.,	  2004;	  Garcia-­‐Calvo	  et	  al.,	  2005).	  Intestinal	  uptake	  of	  dietary	  cholesterol	  is	  followed	  by	  cholesterol	  esterification	  by	  acyl-­‐Coenzyme	  A:cholesterol	  acyltransferase	  (ACAT)	  2	  in	  the	  endoplasmic	  reticulum	  (ER)	  in	  enterocytes	  and	   assembled	   into	   chylomicron	   particles	   for	   transportation	   to	   the	   liver,	   cardiac,	   and	  skeletal	  muscle	  tissues	  (Nguyen	  et	  al.,	  2012).	  	  	  
1.1.2	  Cholesterol	  balance	  in	  peripheral	  cells	  and	  the	  CNS	  	  	  Body	  cholesterol	  can	  be	  redistributed	  among	  tissues	  via	  the	  blood	  circulation.	  Due	  to	  the	  hydrophobic	   property	   of	   cholesterol,	   it	   must	   associate	   with	   lipid-­‐loaded	   lipoprotein	  particles	   to	   be	   transported	   in	   the	   circulation.	   The	   low-­‐density	   lipoprotein	   receptor	  (LDLr),	   which	   was	   identified	   in	   the	   late	   1970s	   (Goldstein	   and	   Brown,	   2009),	   is	   the	  receptor	  for	  LDL-­‐bound	  cholesterol	  uptake	  and	  internalization	  in	  the	  peripheral	  tissues.	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Excessive	   cholesterol	   in	   peripheral	   tissues	   and	  macrophages	   can	  be	  delivered	  back	   to	  the	  liver	  via	  reverse	  cholesterol	  transport	  (RCT)	  and	  then	  secreted	  via	  the	  bile	  into	  the	  feces	   (Glomset,	   1968).	   Alternatively,	   peripheral	   cholesterol	   can	   also	   be	   directly	  transported	   through	   the	   intestinal	   wall	   via	   transintestinal	   cholesterol	   excretion,	  although	   this	   pathway	   has	   not	   been	   fully	   elucidated	   at	   the	   molecular	   level	   (van	   der	  Velde	  et	  al.,	  2010).	  	  RCT	   is	  a	  multistep	  process	   largely	  mediated	  by	  high-­‐density	   lipoprotein	  (HDL).	  HDL	   is	  produced	  in	  the	  liver	  and	  intestine	  in	  a	  lipid-­‐poor	  discoidal	  form	  (pre-­‐β	  HDL),	  which	  can	  be	   loaded	   with	   free	   cholesterol	   (FC)	   and	   phospholipids	   from	   the	   peripheral	   tissues.	  Apolipoprotein	  A-­‐I	   (ApoA-­‐I),	   a	   lipoprotein	   located	   in	   the	   nascent	   pre-­‐β	   HDL,	   interacts	  with	  ATP-­‐binding	  cassette	   transporter	  A1	  (ABCA1)	   that	  promotes	  cholesterol	  efflux	   to	  the	  HDL	  (Brunham	  et	  al.,	  2006),	  and	  ATP-­‐binding	  cassette	  transporter	  G1	  (ABCG1)	  that	  aids	   in	   cholesterol	   transfer.	   ApoA-­‐I	   also	   activates	   lecithin-­‐cholesterol	   acyltransferase	  (LCAT)	   to	  esterify	  FC	   in	   the	  pre-­‐β	  HDL	   into	  cholesteryl	  ester	   (CE),	   thus	  promoting	   the	  formation	   of	   mature	   spherical	   HDL	   (HDL2)	   (Calabresi	   and	   Franceschini,	   2010).	   HDL-­‐borne	   FC/CE	   can	   be	   taken	   up	   by	   scavenger	   receptor	   type-­‐BI	   (SR-­‐BI),	   a	   cell-­‐surface	  receptor	  mainly	  expressed	  in	  the	  liver	  and	  steroidogenic	  tissues,	  and	  utilized	  in	  bile	  acid	  generation	   and	   steroid	   hormone	   synthesis,	   respectively	   (Kozarsky	   et	   al.,	   1997).	   HDL	  binds	  to	  SR-­‐BI	  and	  allows	  delivery	  of	  FC	  and	  CE	  to	  the	  plasma	  membrane	  (PM)	  without	  internalization	   of	   the	   HDL	   particle	   (Connelly	   and	   Williams,	   2003).	   Moreover,	   HDL2-­‐bound	  CE	  in	  hepatocytes	  can	  be	  transferred	  to	  the	  LDL	  and	  very	  low-­‐density	  lipoprotein	  (VLDL)	   particles	   and	   then	   enter	   the	   LDLr	   pathway.	   This	   step	   is	   largely	   facilitated	   by	  cholesteryl	  ester	  transfer	  protein	  (CETP).	  	  	  Adipose	  tissue	  is	  the	  largest	  cholesterol	  pool	  (as	  much	  as	  25%)	  in	  the	  body;	  it	  also	  acts	  as	   a	   reservoir	   for	   triacylglycerides.	   Adipose	   tissue	   is	   important	   in	   preserving	   excess	  energy	  and	  avoiding	  lipotoxicity.	  Cholesterol	  synthesis	  rates	  are	  low	  in	  adipocytes.	  Most	  adipocyte	  cholesterol	  comes	  from	  circulating	  lipoproteins,	  e.g.	  HDL	  via	  SR-­‐BI	  (Dagher	  et	  al.,	   2003)	   and	   LDLr-­‐related	   protein	   (LRP),	   oxidized	   LDL	   via	   SR-­‐BI	   and	   CD36,	   another	  member	   in	   the	   class	   B	   scavenger	   receptor	   family.	   Imbalance	   of	   cholesterol	   and	   other	  neutral	   lipids	   in	   lipid	   droplets	   (LDs),	   the	   specialized	   organelles	   in	   the	   adipose	   tissue,	  leads	  to	  adipocyte	  dysfunction,	  obesity,	  and	  insulin	  resistance	  (Greenberg	  et	  al.,	  2011).	  	  	  The	   central	   nervous	   system	   (CNS)	   has	   its	   own	   manner	   of	   cholesterol	   synthesis	  regulation	   and	   maintenance,	   since	   the	   blood-­‐brain	   barrier	   (BBB)	   blocks	   most	  cholesterol	   exchange	   between	   the	   CNS	   and	   the	   rest	   of	   the	   body.	   The	   CNS	   needs	  substantial	   amount	   of	   cholesterol	   for	   the	   important	   roles	   cholesterol	   plays	   in	  modulating	   axon	   and	   dendrite	   outgrowth,	   neuronal	   polarity,	   as	   well	   as	   being	   a	   key	  component	  in	  synaptic	  membranes	  and	  myelin	  that	  contribute	  to	  electrical	  signaling	  in	  neurons	   (Dietschy	   and	   Turley,	   2001).	   Both	   glial	   cells	   and	   neurons	   can	   synthesize	  cholesterol	   in	  situ.	  However,	  unlike	  newborn	  neurons	  that	  produce	  cholesterol	  actively	  for	   survival,	   neurons	   in	   the	   postnatal	  mouse	   brain	   have	   a	   lower	   sterol	   synthesis	   rate	  than	  glial	  cells,	  and	  the	  latter	  are	  considered	  as	  the	  major	  cholesterol	  producer	  (Nieweg	  et	  al.,	  2009).	  The	   lipid	  communication	  between	  astrocytes	  and	  neurons	  also	  occurs	  via	  lipoproteins	   presenting	   different	   apolipoproteins:	   ApoE,	  which	   is	  mainly	   generated	   in	  astrocytes,	  and	  ApoJ/ApoD,	  which	  are	  produced	  by	  both	  astrocytes	  and	  neurons.	  ApoE	  particles	  are	  larger	  than	  those	  harboring	  ApoJ	  and	  are	  required	  for	  lipid	  secretion	  from	  astrocytes	  (Fagan	  et	  al.,	  1999).	  	  	  




1.2	  Transcriptional	  regulation	  of	  sterol	  metabolism	  	  Cholesterol	  metabolism	  is	  one	  of	  the	  most	  strictly	  regulated	  processes	  in	  cells,	  occurring	  through	   feedback	   regulation.	   The	   central	   proteins	   in	   this	   system	  are	   sterol	   regulatory	  element-­‐binding	   proteins	   (SREBPs).	   In	   vertebrates,	   SREBP1	   activates	   fatty	   acid	  synthesis,	  whereas	  SREBP2	  mainly	  activates	   cholesterol	   synthesis	  and	  uptake	   (Horton	  et	  al.,	  2002)	  by	  regulating	  transcription	  of	  target	  genes.	  	  	  SREBP	  resides	  in	  the	  ER	  membrane	  with	  both	  N-­‐terminal	  basic-­‐helix-­‐loop-­‐helix-­‐leucine	  zipper	   (bHLH-­‐Zip)	   and	   C-­‐terminus	   projecting	   into	   the	   cytosol.	   It	   binds	   to	  SREBP	  cleavage-­‐activating	   protein	  (SCAP),	   which	   is	   retained	   by insulin-­‐induced	  gene	  1	  (Insig-­‐1)	  under	  basal	  conditions	  with	  ample	  cholesterol.	   In	  sterol-­‐deprived	  cells	  where	  the	   ER	   cholesterol	   level	   drops	   to	   5%	   of	   the	   total	   ER	   lipids,	   SCAP	   binds	   to	   coatomer	  protein	  complex	  II	  (COPII)	  and	  leaves	  the	  ER	  via	  COPII-­‐coated	  vesicles.	  SCAP	  transports	  SREBP	  from	  the	  ER	  to	  the	  Golgi,	  where	  site-­‐1	  protease	  (S1P)	  first	  cleaves	  SREBP	  in	  the	  lumen-­‐projecting	   hydrophilic	   loop,	   and	   S2P	   makes	   the	   second	   cleavage	   within	   the	  membrane,	   generating	   the	   free	   bHLH-­‐Zip	   domain	   (mature	   form	   of	   SREBP).	   Mature	  SREBP	   then	   translocates	   to	   the	   nucleus,	   where	   it	   interacts	   with	   the	   sterol	   response	  element	  (SRE)	   in	   target	  genes,	  which	  was	   first	   identified	   in	   the	  enhancer	  region	  of	   the	  LDLr	  promoter	  sequence	  (Sudhof	  et	  al.,	  1987)	  and	  initiates	  transcription	  of	  target	  genes.	  	  Mature	   SREBP	   continuously	   activates	   gene	   transcription	   until	   a	   sufficient	   amount	   of	  Insig-­‐1	   protein,	   which	   is	   also	   a	   transcriptional	   target	   of	   SREBP,	   has	   been	   produced.	  Insig-­‐1	   and	   SCAP	   sense	   the	   cellular	   sterol	   levels	   by	   direct	   binding	  with	   oxysterol	   and	  cholesterol,	  respectively,	   in	  their	  sterol-­‐sensing	  domain,	  and	  then	  trigger	  Insig-­‐1/SCAP	  interaction.	  This	  leads	  to	  a	  conformational	  change	  in	  the	  cytoplasmic	  region	  of	  SCAP	  and	  dissociates	   it	   from	   the	   COPII	   proteins,	   hence	   it	   retains	   SREBP	   in	   the	   ER	   (Brown	   and	  Goldstein,	  2009).	  	  In	   addition	   to	   transcriptional	   regulation	   of	   cholesterol	   synthesis,	   cells	   have	   also	  developed	  a	  similar	   feedback	  system	   for	  controlling	  excessive	  cholesterol	  efflux	   to	   the	  environment.	   Two	   proteins	   facilitating	   the	   efflux,	   ABCA1	   and	   ABCG1,	   are	  transcriptionally	   regulated	   by	   liver	   X	   receptors	   (LXRs).	   LXR	   also	   helps	   in	   suppressing	  cholesterol	   uptake	  by	   transcriptionally	   inducing	   Idol	   (inducible	  degrader	  of	   the	  LDLr)	  expression	   and	   triggering	   LDLr	   ubiquitination	   and	   degradation	   (Zelcer	   et	   al.,	   2009).	  LXRs	   (LXRα	  and	  LXRβ)	  belong	   to	   the	  nuclear	   receptor	   superfamily	  of	   ligand-­‐activated	  transcription	   factors.	   LXRs	   use	   oxysterols	   as	   ligands	   to	   sense	   the	   increased	   cellular	  cholesterol	   level	  and	  activate	  gene	  expression	  to	  protect	  cells	   from	  cholesterol	  surplus	  (Janowski	   et	   al.,	   1996).	   To	   initiate	   gene	   transcription,	   LXR	   heterodimerizes	   with	   the	  retinoid	   X	   receptor,	   resulting	   in	   a	   conformational	   change	   to	   recruit	   nuclear	   receptor	  coactivators	  for	  transcription	  activation	  (Yang	  et	  al.,	  2006).	  	  
1.3	  Cholesterol	  biosynthesis	  	  	  Cholesterol	  biosynthesis	   is	  a	  complex	  multistep	  process	   involving	  35	  enzymes	  (Gaylor,	  2002)	  that	  are	  commonly	  found	  in	  the	  ER	  (Reinhart	  et	  al.,	  1987).	  Several	  of	  these	  have	  been	   identified	   as	   rate-­‐limiting	   enzymes	   for	   the	   entire	   synthesis	   pathway	   (Figure	   2).	  Squalene	  epoxidase	  (SQLE)	  catalyzes	  the	  first	  oxygenation	  step	  in	  the	  synthesis	  pathway;	  3-­‐hydroxy-­‐3-­‐methyl-­‐glutaryl-­‐CoA	   reductase	  	   (HMGR)	   converts	   HMG-­‐CoA	   to	   mevalonic	  acid;	  lanosterol	  demethylase	  (CYP51),	  a	  cytochrome	  P450	  family	  enzyme,	  catalyzes	  the	  first	   step	   after	   cyclization;	   24-­‐dehydrocholesterol	   reductase	   (DHCR24)	   catalyzes	   the	  
	  	  	  
	  
12	  
reduction	  of	  the	  Δ24	  double	  bond	  in	  sterol	  intermediates,	  converting	  from	  desmosterol	  to	   cholesterol;	   and	   7-­‐dehydrocholesterol	   reductase	   (DHCR7)	   catalyzes	   7-­‐dehydrocholesterol	   (7-­‐DHC)	   to	   cholesterol.	   Due	   to	   its	   importance	   in	   the	   cholesterol	  synthesis	  pathway,	  HMGR	  has	  been	  made	   the	  acting	   target	  of	   the	  cholesterol-­‐lowering	  drugs,	  statins	  (Tobert,	  2003).	  After	  lanosterol	  synthesis,	  the	  pathway	  is	  divided	  into	  the	  Bloch	   (Bloch,	   1965)	   and	   Kandutsch-­‐Russell	   (Kandutsch	   and	   Russell,	   1960)	   pathways,	  which	  differ	  at	  the	  steps	  of	  the	  Δ24	  double	  bond	  being	  reduced.	  The	  Δ24	  double	  bond	  of	  sterol	  intermediates	  in	  the	  Bloch	  pathway	  can	  be	  removed	  by	  DHCR24,	  which	  converts	  from	  the	  Bloch	  to	  the	  Kandutsch-­‐Russell	  pathway.	  	  	  Minor	   structural	   differences	   between	   cholesterol	   and	   its	   precursors	   along	   the	  biosynthetic	   pathways,	   e.g.	   position	   of	   the	   double	   bond,	   may	   result	   in	   considerable	  alteration	   of	   membrane	   organization	   and	   dynamics	   (Vainio	   et	   al.,	   2006).	   Therefore,	  accumulation	  of	  cholesterol	  precursors	  would	  lead	  to	  serious	  pathological	  consequences,	  as	   seen	   in	   severe	   inborn	   diseases	   due	   to	   cholesterol	   synthesis	   enzyme	   deficiencies	  (Herman,	  2003).	  	  	  
Figure	  2.	  Schematic	  illustration	  of	  cholesterol	  synthesis	  pathway.	  	  
	  	  	  
1.4	  Cholesterol	  uptake	  and	  intracellular	  cholesterol	  transport	  
	  Cells	  take	  up	  LDL-­‐associated	  cholesterol	  from	  plasma	  via	  LDLr,	  the	  process	  of	  which	  has	  been	   studied	   extensively	   as	   a	   classic	   model	   for	   receptor-­‐mediated	   endocytosis	  (Goldstein	   et	   al.,	   1985).	   The	   LDL	   receptors	   cluster	   in	   clathrin-­‐coated	   pits.	   During	  external	  LDL	  binding,	  complexes	  of	  LDL	  and	  the	  receptor	  are	  internalized	  to	  the	  cell	  via	  clathrin-­‐coated	  vesicles.	  These	  complexes	   then	  enter	   the	  endocytic	  pathway	  until	   they	  reach	   the	   lysosome,	  where	   the	  receptors	  disassociate	   from	  the	  complexes	  and	   the	  CEs	  become	  hydrolyzed	  into	  FC	  and	  fatty	  acids	  by	  lysosomal	  acid	  lipase	  (LAL)	  at	  low	  pH.	  The	  disassociated	  LDL	  receptors	  are	  recycled	  back	  to	  the	  PM	  via	  vesicles	  budding	  from	  the	  endosomes	  and	  ready	  to	  be	  reused	  for	  the	  next	  binding	  event.	  	  	  Niemann-­‐Pick	  disease	  type	  C	  protein	  (NPC)	  1	  and	  NPC2	  are	  two	  lysosomal	  proteins	  that	  have	  been	  identified	  as	  FC	  transporters.	  NPC1	  is	  a	  transmembrane	  protein	  with	  a	  sterol-­‐sensing	  domain	  and	  is	  considered	  as	  a	  lipid	  permease	  (Davies	  et	  al.,	  2000).	  NPC2	  protein	  is	  soluble	  with	  a	  high	  cholesterol-­‐binding	  affinity	  (Ko	  et	  al.,	  2003).	  X-­‐ray	  crystallography	  shows	   that	   NPC2	   binds	   cholesterol	   with	   its	   isooctyl	   side	   chain	   buried	   and	   its	   3β-­‐hydroxyl	  chain	  exposed,	  while	  the	  N-­‐terminal	  domain	  of	  NPC1	  binds	  cholesterol	   in	  the	  opposite	  orientation	  (Kwon	  et	  al.,	  2009).	  A	  model	  of	  how	  NPC1	  and	  NPC2	  act	  in	  tandem	  in	   transferring	   cholesterol	   has	   been	   proposed:	   NPC2	   delivers	   cholesterol	   to	   NPC1	   by	  
	  	  	  
	  
13	  
direct	  interaction	  at	  their	  surface	  patches	  to	  allow	  a	  ‘hydrophobic	  handoff’	  (Wang	  et	  al.,	  2010).	  	  	  After	  being	  liberated	  from	  lyso/endosomes,	  cholesterol	   is	  transported	  to	  the	  ER	  or	  PM	  (Ikonen,	   2008).	   Several	   players	   in	   the	   cholesterol	   trafficking	   en	   route	   to	   the	   ER	   have	  been	  proposed	  (Du	  et	  al.,	  2013;	  Du	  et	  al.,	  2011);	  however,	  the	  mechinery	  of	  cholesterol	  transport	   to	   the	   PM	   was	   still	   lacking.	   Recently,	   Rab8a,	   a	   small	   GTPase	   involved	   in	  vesicular	   traffic,	   and	   its	   interaction	  partners	  have	  been	   identified	   as	   key	   regulators	   of	  postendosomal	   cholesterol	   transport	   to	   the	   PM,	   using	   BODIPY-­‐labeled	   CE	   as	   tracers	  (Kanerva	  et	  al.,	  2013).	  	  The	  cholesterol	  released	  from	  the	  lysosomes	  forms	  a	  sterol	  pool	  representing	   the	   cellular	   sterol	   level,	   which	   can	   be	   sensed	   by	   SREBP2-­‐mediated	  feedback	  regulation	  of	  sterol	  synthesis.	  The	  FC	  is	  also	  subjected	  to	  Acyl-­‐CoA:cholesterol	  acyltransferase	  (ACAT)	  for	  reesterification	  to	  maintain	  the	  unesterified	  cholesterol	  at	  a	  constant	  level.	  
	  
1.5	  Inborn	  errors	  of	  cholesterol	  metabolism	  
	  Familial	   hypercholesterolemia	   (FH,	   OMIM	   143890)	   is	   an	   autosomal	   dominant	   genetic	  disorder	   leading	   to	   a	   deficiency	   in	   removing	   LDL-­‐cholesterol	   from	   the	   circulation.	  Homozygous	  FH	  is	  rare	  and	  found	  in	  1	  per	  million	  individuals.	  Heterozygous	  FH,	  as	  the	  most	   common	   inborn	   error	   of	   cholesterol	   metabolism,	   has	   a	   high	   incidence	   of	   1:500	  among	  the	  general	  population,	  resulting	  in	  50%	  risk	  of	  coronary	  artery	  disease	  in	  males	  and	  30%	  in	   females	  by	  age	  60,	   compared	  with	  13%	  and	  9%	   in	   their	  non-­‐FH	  relatives,	  respectively	   (Stone	   et	   al.,	   1974).	   The	   genetic	   causes	   of	   FH	   are	   found	   in	   mutations	   of	  several	   genes,	   with	   LDLr	   gene	   mutations	   as	   the	   major	   phenotype.	   Over	   700	   LDLr	  mutations	   have	   been	   identified	   in	   FH	   patients	   (Heath	   et	   al.,	   2001);	   however,	   these	  account	   for	   only	   30-­‐50%	   of	   the	   phenotype	   in	   diagnosed	   patients.	   In	   addition	   to	  LDLr	  gene	   mutations,	   rare	   mutations	   in	   LDLr	   ligand	   ApoB	   (LDL	   binding),	   protease	   PCSK9	  (LDLr	   protein	   level)	   (Abifadel	   et	   al.,	   2003),	   and	   autosomal	   recessive	  hypercholesterolemia	  	   (LDLr	   internalization)	   (Garcia	   et	   al.,	   2001)	   have	   also	   been	  recognized	   in	   FH,	   and	   more	   unidentified	   genes	   are	   expected.	   Statin,	   the	   inhibitor	   of	  HMGR,	   has	   been	   extensively	   used	   in	   treating	   both	   homozygous	   (Marais	   et	   al.,	   1997b)	  and	   heterozygous	   (Marais	   et	   al.,	   1997a)	   FH	   for	   its	   effectiveness	   in	   reducing	   LDL-­‐cholesterol.	  	  Cholesterol	   biosynthesis	   disorders	   rising	   from	   inborn	   cholesterol	   synthesis	   enzyme	  defects	   are	   usually	   associated	   with	   developmental	   malformation.	   The	   first	   described,	  and	  by	   far	   the	  most	   common	  disorder	  of	  postsqualene	   cholesterol	  biosynthesis,	   is	   the	  Smith-­‐Lemli-­‐Opitz	   syndrome	   (SLOS,	   OMIM	   270400),	  manifesting	   as	   decreased	   plasma	  cholesterol	   and	   increased	   7-­‐DHC	   levels,	   due	   to	   DHCR7	   deficiency	   in	   the	   final	   step	   of	  cholesterol	  synthesis.	  SLOS	  has	  a	  broad	  clinical	  spectrum,	  from	  minor	  physical	  stigmata	  to	   prenatal/neonatal	   death	   due	   to	   multiple	   malformations	   (Porter,	   2003).	   Two	   other	  cholesterol	   biosynthesis	   disorders,	   desmosterolosis	   and	   lathosterolosis,	   have	   been	  reported	   in	  only	  a	   few	  patients,	  but	  have	   features	  reminiscent	  of	  SLOS.	  Both	  disorders	  are	  deficient	  in	  the	  last	  steps	  of	  cholesterol	  synthesis,	  resulting	  in	  accumulating	  plasma	  desmosterol	   or	   lathosterol.	   In	   comparison	   to	   earlier	   deficiencies	   in	   cholesterol	  biosynthesis,	   e.g.	   congenital	   hemidysplasia	  with	   ichthyosiform	  erythroderma	  or	  nevus	  and	  limb	  defects	  (CHILD	  syndrome,	  OMIM	  308050),	  later	  deficiencies	  are	  clinically	  more	  severe	   (Ikonen,	   2006).	   The	   severe	   developmental	   failure	   found	   in	   these	   cholesterol	  biosynthesis	   disorders	   could	   be	   explained	   at	   least	   partially	   by	   the	   fact	   that	   covalent	  cholesterol	   modification	   of	   Hedgehog	   is	   necessary	   for	   Hedgehog	   processing	   and	  functioning,	  which	  plays	  a	  central	  role	  in	  development.	  SLOS	  and	  lathosterolosis	  display	  diminished	  Hedgehog	  signaling	  (Cooper	  et	  al.,	  2003).	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  LAL	   deficiency	   (OMIM	   278000)	   causes	   two	   distinct	   autosomal	   recessive	   disorders	   in	  humans:	  cholesteryl	  ester	  storage	  disease	  (CESD)	  and	  Wolman	  disease	  (WD).	  LAL	  is	  the	  crucial	   enzyme	   for	   hydrolysis	   of	   CE	   and	   triacylglycerides	   and	   is	   posttranslationally	  targeted	   to	   lysosomes	   via	   the	   mannose-­‐6-­‐phosphate	   receptor.	   Both	   CESD	   and	   WD	  manifest	   as	   accumulation	   of	   CE	   and	   triglycerides	   in	   a	   variety	   of	   tissues,	   such	   as	   liver,	  spleen,	   and	   small	   intestine.	   CESD	   is	   benign	   with	   late	   onset	   and	   may	   only	   display	  hepatomegaly,	   whereas	   WD	   is	   lethal	   with	   infantile	   onset,	   exhibiting	  hepatosplenomegaly,	   steatorrhea,	   abdominal	   distention,	   and	   bilateral	   adrenal	  calcification	  (Du	  et	  al.,	  1998).	  This	  suggests	  that	  there	  may	  be	  other	  factors	  accounting	  for	   the	   clinical	   heterogeneities	   between	   CESD	   and	  WD.	   For	   example,	   the	   activities	   of	  hepatic	  acid	   lipase	  and	  neutral	   lipase	  are	  quite	  unlike	   in	   the	   two	  diseases	  (Hoeg	  et	  al.,	  1984).	  	  NPC	   (OMIM	   257220)	   is	   a	   fatal	   neurodegenerative	   disorder	   with	   approximately	  1/150000	   birth	   incidence.	   Genetic	   analysis	   shows	   that	   95%	   of	   the	   cases	   result	   from	  
NPC1	   gene	  mutations,	  with	   the	  other	  5%	   from	  NPC2	  mutations.	  Both	  NPC1	  and	  NPC2	  mutations	  lead	  to	  deficiency	  in	  lipid	  egress	  from	  late	  endosomes	  and	  lysosomes	  (Vance,	  2006).	   In	   NPC	   patient	   fibroblasts,	   LDL	   uptake	   and	   internalization	   into	   late	  endosomes/lysosomes	   are	   not	   impaired,	   and	   although	   ACAT	   activity	   appears	   normal	  cholesterol	   esterification	   is	   deficient	   (Pentchev	   et	   al.,	   1985).	   Cytochemical	   analyses	  show	   massive	   cholesterol	   accumulation	   in	   late	   endosomes/lysosomes	   of	   NPC	   cells	  (Blanchette-­‐Mackie	  et	  al.,	  1988).	  Consequently,	  NPC	  fibroblasts	  do	  not	  respond	  to	  LDL-­‐mediated	   feedback	   regulation	   of	   cholesterol	   synthesis	   and	   LDLr	   activity,	   resulting	   in	  cellular	  cholesterol	  accumulation	  (Lindenthal	  et	  al.,	  2001).	  	  
2.	  Desmosterol	  and	  steroid	  hormones	  
	  
2.1	  Desmosterol	  	  
	  Desmosterol	  is	  an	  immediate	  precursor	  of	  cholesterol	  in	  the	  Bloch	  pathway	  with	  a	  Δ24	  double-­‐bond	  difference	  that	  can	  be	  removed	  by	  DHCR24,	  otherwise	  their	  structures	  are	  identical	   (Figure	   3).	   However,	   cholesterol	   and	   desmosterol	   exhibit	   considerably	  different	   biophysical	   and	   functional	   characteristics.	   A	   desmosterol-­‐composed	  membrane	  shows	  much	  less	  ordering	  and	  insolubility	  than	  those	  of	  cholesterol	  (Vainio	  et	   al.,	   2006).	   Replacing	   cholesterol	   with	   desmosterol	   leads	   to	   a	   perturbed	   caveolar	  structure,	   although	   caveolar	   ligand	   uptake	   is	   only	  moderately	   inhibited	   (Jansen	   et	   al.,	  2008).	  	  
Figure	  3.	  Molecular	  structure	  of	  desmosterol.	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Desmosterol	  is	  an	  important	  regulator	  in	  cholesterol	  balance;	  it	  acts	  as	  a	  ligand	  of	  LXR	  by	   directly	   binding	   to	   LXRα/β	   and	   facilitating	   recruitment	   of	   steroid	   receptor	  coactivator	  1.	  The	  unsaturated	  side	  chain	  of	  desmosterol	  is	  sufficient	  and	  the	  oxysterol	  side	   chain	   is	   not	   necessary	   for	   desmosterol-­‐induced	   LXR	   activation.	   Desmosterol	   also	  suppresses	   the	   expression	   of	   LDLr	   and	   HMGR	   by	   reducing	   SREBP2	   processing.	   The	  effects	  of	  desmosterol	  on	  regulating	  ABCA1	  expression	  via	  LXR	  and	  LDLr	  expression	  via	  SREBP2	  are	  dose-­‐dependent	  (Yang	  et	  al.,	  2006).	  	  
	  
2.2	  Steroid	  hormone	  precursors	  




















Figure	  4.	  Schematic	  illustration	  of	  steroidogenesis	  from	  cholesterol.	  	  
	  
2.3	  Metabolism	  of	  DHEA	  
	  DHEA	  is	  a	  major	  steroid	  in	  the	  circulation	  and	  the	  precursor	  of	  androgen	  and	  estrogen.	  DHEA	  is	  primarily	  produced	  in	  the	  adrenal	  gland	  and	  partly	  in	  the	  ovaries	  (Labrie	  et	  al.,	  2003).	  Metabolism	  of	  DHEA	  is	  also	  dependent	  on	  HSDs	  and	  cytochrome	  P450	  enzymes	  (Figure	   4).	   The	   reductase	   17βHSD1	   and	   oxidase	   17βHSD2	   are	   responsible	   for	   the	  interconversion	  of	  DHEA	  and	  androstenediol.	  The	  17βHSD2	  also	  catalyzes	  the	  oxidation	  of	  testosterone,	  estradiol,	  and	  dihydrotestosterone.	  The	  oxidative	  activity	  of	  17βHSD2	  is	  believed	   to	   play	   a	   physiological	   role	   in	   protecting	   tissues	   from	   being	   exposed	   to	  excessive	   active	   steroid	   hormones	   (Peltoketo	   et	   al.,	   1999).	   DHEA	   and	   androstenediol	  can	   be	   converted	   to	   androgens	   (androstenedione	   and	   testosterone,	   respectively)	   by	  3βHSD,	   and	   the	   androgens	   can	   then	   undergo	   aromatization	   by	   P450	   aromatase	  (P450aro)	   to	   produce	   estrogens	   (estrone	   and	   estradiol,	   respectively).	   P450aro	   is	  ubiquitously	   expressed	   in	   both	   steroidogenic	   and	   nonsteroidogenic	   tissues,	   but	   its	  expression	   is	   diversely	   regulated	   in	   different	   tissues	   under	   different	   hormone	  stimulations.	   For	   instance,	   the	   two-­‐cell	   theory	   of	   human	   estrogen	   synthesis	   suggests	  that	  most	  androstenedione	  synthesized	  in	  ovarian	  theca	  cells	  is	  converted	  to	  estrone	  by	  P450aro	  in	  granulosa	  cells	  (Hickey	  et	  al.,	  1989).	  	  DHEA	  can	  exit	  the	  steroidogenic	  pathway	  by	  being	  sulfated	  in	  its	  3β-­‐hydroxyl	  group	  by	  a	  sulfotransferase	  (e.g.	  SULT2A1),	  and	  DHEA	  sulfate	  (DHEAS)	  can	  be	  hydrolyzed	  to	  DHEA	  by	  steroid	  sulfatase	  (STS).	  The	  major	  sites	  for	  DHEA	  sulfation	  are	  the	  adrenal	  gland	  and	  liver.	   In	   comparison	   to	   DHEA,	   DHEAS	   usually	   has	   a	   very	   high	   concentration	   in	   the	  plasma.	   Since	   only	   free	   DHEA,	   but	   not	   DHEAS,	   is	   a	   substrate	   for	   the	   3βHSD,	   the	  accumulation	  of	  DHEA	  leads	  to	  androgenesis.	  	  	  DHEA	   also	   exists	   in	   the	   form	   of	   DHEA-­‐fatty	   acyl	   esters	   (DHEA-­‐FAEs)	  with	   nanomolar	  concentrations	  in	  the	  blood.	  DHEA	  is	  esterified	  by	  plasma	  LCAT,	  and	  ~46%	  of	  the	  DHEA-­‐FAE	  is	  associated	  with	  LDL	  particles	  and	  ~37%	  with	  HDL	  (Lavallee	  et	  al.,	  1996;	  Roy	  and	  Belanger,	  1989).	  DHEA-­‐FAE	  can	  be	  transferred	  from	  HDL	  to	  VLDL	  and	  LDL	  by	  a	  CETP-­‐independent	  mechanism	  (Provost	  et	  al.,	  1997).	  Lipoprotein-­‐associated	  DHEA-­‐FAE	  is	  the	  major	   form	   of	   DHEA	   to	   enter	   the	   cells	   via	   the	   receptor-­‐mediated	   internalization	  pathway	  (Leszczynski	  et	  al.,	  1989).	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2.4	  Physiological	  functions	  of	  DHEA	  	  Many	  studies	  have	  shown	  that	  DHEA	  is	  a	  steroid	  with	  multiple	  effects.	  DHEA	  and	  DHEAS	  are	  able	  to	  reduce	  inflammation	  and	  enhance	  immunity.	  In	  a	  human	  study,	  serum	  DHEA	  and	  DHEAS	  levels	  level	  are	  inversely	  correlated	  with	  that	  of	  interleukin-­‐6	  (IL-­‐6),	  one	  of	  the	  pathogenic	  factors	  in	  inflammatory	  and	  age-­‐related	  diseases	  (Straub	  et	  al.,	  1998).	  In	  aged	  mice,	  a	  DHEAS	  supplement	  can	  prevent	  and/or	  reverse	  the	  lowered	  regulation	  of	  IL-­‐6	  production	  (Daynes	  et	  al.,	  1993).	  DHEA	  also	  inhibits	  other	  inflammatory	  cytokines,	  e.g.	  tumor	  necrosis	  factor	  and	  natural	  killer	  cell	  cytokine,	  in	  various	  cell	  types	  (Iwasaki	  et	  al.,	  2004).	  	  As	  the	  precursor	  of	  the	  estrogens	  and	  androgens	  that	  are	  implicated	  in	  mitogenesis	  and	  tumorigenesis,	   DHEA	   may	   play	   a	   role	   in	   tumor	   growth,	   although	   this	   is	   still	  controversial.	   A	   mouse	   study	   showed	   no	   correlation	   between	   DHEAS	   administration	  (with	  consequent	  high	  DHEAS	  and	  DHEA	  concentrations)	  and	  cancer	  incidence	  (Pugh	  et	  al.,	  1999).	  However,	  the	  anticarcinogenic	  activity	  of	  DHEA	  in	  inhibiting	  the	  cell	  cycle	  and	  in	  protecting	  from	  breast	  cancer	  has	  been	  shown	  in	  a	  variety	  of	  cancer	  cells	  (Labrie	  et	  al.,	  2003).	   In	   contrast,	   a	   large-­‐scale	   study	   showed	   no	   association	   between	   DHEAS/DHEA	  and	   breast	   cancer	   risk	   overall,	   but	   was	   positively	   associated	   with	  estrogen/progesterone	   receptor-­‐positive	   breast	   cancer	   (Tworoger	   et	   al.,	   2006).	   The	  conflicting	  results	  indicate	  that	  other	  factors,	  e.g.	  estrogen	  level	  and	  age,	  may	  impact	  the	  correlation	   of	   DHEA	   and	   cancer	   risk.	   	   Since	   STS	   frees	   active	   estrone	   and	   DHEA	   from	  their	   inert	   sulfate	   forms,	   it	   may	   be	   important	   in	   inhibiting	   tumorigenesis	   (Miller	   and	  Auchus,	  2011).	  	  	  	  DHEA	   may	   have	   a	   therapeutic	   effect	   on	   diabetes.	   In	   a	   diabetic	   mouse	   model,	   DHEA	  feeding	   increased	   insulin	  sensitivity	  and	  prevented	  the	  pathogenic	  aspects	  of	  diabetes,	  such	  as	  hyperglycemia	  and	  β-­‐cell	  necrosis	  (Coleman	  et	  al.,	  1982).	  DHEA	  treatment	  in	  an	  obese	  mouse	  model	  showed	  that	  DHEA	  not	  only	  reduces	  body	  weight	  but	  also	  decreases	  serum	   tumor	   necrosis	   factor-­‐α,	   which	   plays	   an	   important	   role	   in	   insulin	   resistance.	  These	  two	  independent	  regulations	  by	  DHEA	  both	  improved	  insulin	  sensitivity	  (Kimura	  et	  al.,	  1998).	  	  	  There	   have	   been	   investigations	   of	   DHEA	   as	   a	   neurosteroid	   in	   the	   brain	   of	   rodents,	  although	   evidence	   in	   the	   human	   brain	   is	   still	   lacking.	   In	   the	   CNS	   of	   rat,	   DHEA	   is	  synthesized	  mostly	  by	  astrocytes	  and	  moderately	  by	  neurons,	  but	  not	  oligodendrocytes.	  This	   positively	   correlates	  with	  P450c17	  mRNA	   expression	   levels	   in	   these	   cells	   (Zwain	  and	  Yen,	  1999).	  DHEA	  can	  be	  found	  throughout	  all	  brain	  regions	  without	  concentration	  specifications	   and	   has	   multiple	   functions.	   One	   study	   showed	   that	   DHEA	   and	   DHEAS	  could	   stimulate	  outgrowth	  of	  neurite	   that	   respectively	  becomes	  axon	  and	  dendrites	   in	  
vitro	   (Compagnone	   and	  Mellon,	   1998).	   DHEA	   and	  DHEAS	   also	   participate	   in	   neuronal	  protection	   and	   survival	   by	   protecting	   hippocampal	   neurons	   from	   glutamate	   toxicity	  (Kimonides	  et	  al.,	  1998).	  These	  effects	  could	  be	  achieved	  by	  DHEA	  and	  DHEAS	  acting	  as	  agonists	  for	  σ	  receptors	  (Monnet	  et	  al.,	  1995)	  and	  antagonist	  for	  γ-­‐aminobutyric	  acid	  A	  receptors	  (Majewska	  et	  al.,	  1990).	  	  Due	   to	   the	   declining	   concentration	   of	   DHEA	   with	   age,	   and	   its	   protective	   role	   in	   age-­‐related	   disorders	   such	   as	   cardiovascular	   disease	   and	   immunodeficiency,	   DHEA	   is	  considered	  as	  a	  dietary	  supplement.	  DHEA	  may	  prevent	  atherosclerosis	  (Yamakawa	  et	  al.,	   2009)	   and	   improves	   vascular	   endothelial	   and	   insulin	   sensitivity	   (Kawano	   et	   al.,	  2003).	   However,	   larger-­‐scale	   clinical	   studies	   are	   needed	   to	   further	   confirm	   the	  beneficial	  effects	  and	  assess	  the	  side	  effects	  of	  DHEA	  supplements.	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3.	  Cholesterol	  in	  the	  brain	  
	  
3.1	  Cell	  types	  for	  brain	  cholesterol	  processing	  	  About	  23%	  of	  the	  total	  cholesterol	  pool	  in	  the	  human	  body	  is	  located	  in	  the	  human	  brain,	  although	  the	  CNS	  only	  accounts	  for	  2%	  of	  the	  body	  weight	  (Dietschy	  and	  Turley,	  2001).	  Since	   the	   BBB	   prohibits	   traversal	   of	  most	   lipoprotein-­‐associated	   cholesterol	   from	   the	  plasma	  to	  the	  brain,	  cholesterol	  is	  actively	  synthesized	  de	  novo	  in	  both	  neuron	  and	  glial	  cells,	   especially	   in	   the	   newborn	   brain.	   In	   the	   early	   stage	   of	   brain	   development,	   most	  newly	   synthesized	   cholesterol	   is	   used	   for	  myelin	   production	   in	   the	   oligodendrocytes,	  and	   the	   rest	   for	   cell	   proliferation.	   As	   the	   brain	   matures	   and	   myelination	   formation	  significantly	   decreases,	   cholesterol	   de	   novo	   synthesis	   in	   the	   brain	   also	   declines	   to	   a	  lower	  but	  still	  measureable	  level.	  Using	  squalene	  synthase	  knockout	  (KO)	  mice,	  studies	  suggested	   that	   adult	   neurons	   survived	   without	   cholesterol	   synthesis,	   probably	   by	  depending	  on	  glia	  as	  a	  cholesterol	  resource	  (Funfschilling	  et	  al.,	  2007);	  while	  newborn	  neurons	  must	  synthesize	  cholesterol	  autonomously	   (Saito	  et	  al.,	  2009).	  Comparing	   the	  sterol	  profile	   in	  neurons	  and	  astrocytes	  of	  postnatal	   rats	   showed	   that	  neurons	  mainly	  contain	  sterols	  of	  the	  Kandutsch-­‐Russell	  pathway,	  whereas	  astrocytes	  contain	  sterols	  of	  the	   Bloch	   pathway.	   A	   higher	   cholesterol	   synthesis	   rate	   is	   also	   observed	   in	   astrocytes	  than	   in	   neurons:	   in	   astrocytes,	   the	   majority	   of	   newly	   synthesized	   sterols	   are	  accumulated	   as	   cholesterol,	   while	   in	   neurons	   they	   are	   accumulated	   as	   lanosterol	  (Nieweg	  et	  al.,	  2009).	  	  
3.2	  Key	  proteins	  for	  brain	  cholesterol	  processing	  	  In	   the	   brain,	   cholesterol	   recycling	   between	   the	   glial	   cells	   and	   neurons	   is	  mediated	   by	  lipoprotein	  secretion	  and	  uptake.	  In	  this	  process,	  ApoE,	  the	  major	  apolipoprotein	  in	  the	  CNS,	   and	   ABCA1	   produced	   in	   astrocytes	   are	   important	   mediators.	   ApoE	   forms	  cholesterol-­‐enriched	   HDL-­‐like	   lipoproteins,	   and	   ABCA1	   facilitates	   ApoE	   transport	   and	  lipidation.	  In	  ABCA1-­‐/-­‐	  KO	  mice,	  the	  ApoE	  level	  in	  the	  cortex	  and	  cerebrospinal	  fluid	  was	  reduced,	  and	  the	  size	  of	  the	  ApoE-­‐containing	   lipoprotein	  was	  decreased	  (Wahrle	  et	  al.,	  2004).	   Lipoproteins	   secreted	   from	   astrocytes	   contain	   not	   only	   cholesterol	   and	  phospholipids,	  but	  also	  cholesterol	  precursors,	  which	  can	  be	  transported	  to	  neurons	  for	  further	  conversion	  to	  cholesterol.	  	  	  Neurons	   take	   up	   cholesterol	   from	   secreted	   lipoproteins	   via	   LDLr	   for	   nerve	   growth,	  synapse	   formation,	   and	   neuron	   repair.	   Interestingly,	   CNS-­‐specific	   ABCA1-­‐/-­‐	   KO	   mice	  showed	   lower	   plasma	   HDL	   cholesterol	   levels,	   reduced	   brain	   cholesterol	   content,	   and	  enhanced	   brain	   uptake	   of	   CE	   from	   plasma	  HDL.	   It	   is	   presumably	   compensated	   for	   by	  increased	  cholesterol	  transport	  across	  the	  BBB	  through	  brain	  capillary	  endothelial	  cells,	  since	   elevated	   SR-­‐BI	   expression	   in	   the	   brain	   capillaries	   was	   seen	   (Karasinska	   et	   al.,	  2009).	  	  	  The	  other	  two	  ABC	  transporter	  family	  proteins,	  ABCG1	  and	  ABCG4,	  are	  responsible	  for	  removing	   cholesterol	  precursors	  and	  metabolites	  via	   lipoproteins	   from	  astrocytes	  and	  neurons,	  respectively	  (Chen	  et	  al.,	  2013).	  In	  the	  ABCG1-­‐/-­‐	  or	  ABCG4-­‐/-­‐	  mouse	  brain,	  sterol	  levels	   are	   normal.	   However,	   in	   the	   ABCG1-­‐/-­‐/ABCG4-­‐/-­‐	   double-­‐knockout	   (dKO)	   mouse	  brain,	   efflux	   of	   cholesterol	   and	   its	   precursors	   to	   lipoproteins	   is	   impaired,	   cholesterol	  intermediates	   in	   the	   synthesis	   pathway	   are	   accumulated,	   and	   cholesterol	   synthesis	   is	  reduced	   (Wang	  et	   al.,	   2008).	   In	  ABCG1-­‐/-­‐ABCG4-­‐/-­‐	   dKO	  mice	  brain,	  24(S)-­‐,	   25-­‐,	   and	  27-­‐hydroxycholesterol	   (24(S)-­‐,	  25-­‐	  and	  27-­‐OHC)	  are	  significantly	  accumulated,	  suggesting	  that	   ABCG1	   and	   ABCG4	   may	   facilitate	   oxysterol	   efflux	   (Bojanic	   et	   al.,	   2010).	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Accumulation	  of	  desmosterol	  and	  oxysterols,	  which	  are	  known	  as	  LXR	  agonists,	  induces	  ABCA1	  expression	  and	  ApoE	  secretion	  (Wang	  et	  al.,	  2008).	  	  	  The	   brain	   can	   secrete	   excess	   cholesterol	   to	   the	   peripheral	   circulation	   by	   removing	  oxidized	  sterol	  metabolites,	  i.e.	  24S-­‐	  and	  27-­‐OHC,	  through	  the	  BBB.	  The	  oxysterols	  have	  higher	   aqueous	   solubility	   than	   cholesterol	   in	   traversing	   the	   BBB,	   due	   to	   their	   polar	  hydroxyl	   group	   in	   the	   side	   chain.	   Cholesterol	   24-­‐hydroxylase	   (CYP46A1),	   the	   enzyme	  responsible	  for	  generating	  24S-­‐OHC,	  is	  mainly	  located	  in	  the	  brain,	  thus	  most	  24S-­‐OHC	  efflux	   is	   from	   the	   brain	   to	   the	   circulation.	   On	   the	   other	   hand,	   the	   enzyme	   for	   the	  formation	   of	   27-­‐OHC,	   sterol	   27-­‐hydroxylase	   (CYP27A1),	   is	   present	   in	   most	   organs,	  therefore	  27-­‐OHC	  is	  able	  to	  traverse	  bidirectionally	  through	  and	  shows	  a	  net	  flux	  from	  the	  circulation	  to	  the	  brain	  (Heverin	  et	  al.,	  2005).	  	  	  
3.3	  Developmental	  regulation	  of	  sterols	  in	  the	  brain	  	  Brain	  sterol	  levels	  are	  differentially	  regulated	  during	  the	  various	  developmental	  stages.	  It	  has	  been	  known	  since	  1960	  that	  there	  is	  a	  sharp	  accumulation	  of	  desmosterol	  in	  the	  early	   stage	   of	   brain	   development.	  While	   other	   cholesterol	   precursors	   only	   present	   as	  1%	  of	  the	  total	  sterol,	  at	  this	  stage	  the	  desmosterol	  level	  may	  transiently	  increase	  to	  as	  much	  as	  30%	  (Fumagalli	  and	  Paoletti,	  1963).	  Desmosterol	  is	  structurally	  different	  from	  cholesterol,	  resulting	   in	  an	  alteration	   in	  biophysical	  property	  and	  function.	  The	  reason	  for	  desmosterol	  accumulation	  in	  the	  developing	  brain	  has	  remained	  unknown.	  Whether	  it	   is	   merely	   a	   nonfunctional	   by-­‐product	   of	   cholesterol	   synthesis	   or	   regulates	   brain	  growth	  still	  needs	  to	  be	  elucidated.	  	  Cholesterol	   is	   the	  major	  sterol	   in	   the	  brain.	  Maintaining	  an	  optimal	  cholesterol	   level	   is	  crucial	   for	   myelination,	   dendritic	   and	   axonal	   differentiation,	   as	   well	   as	   synaptic	  activation	   in	   the	   brain	   development.	   Myelin	   functions	   as	   an	   electrical	   insulator	   by	  extending	   from	   the	   PM	   of	   oligodendrocytes	   and	   wrapping	   around	   the	   axons.	   Mutant	  oligodendrocytes	  with	  impaired	  cholesterol	  synthesis	  show	  reduced	  cholesterol:	  protein	  ratios	   and	   hypomyelination,	   although	   the	  myelin	   architecture	   is	   undisturbed	   and	   still	  concentrated	  with	  the	  cholesterol.	  This	  indicates	  that	  cholesterol	  is	  essential	  for	  myelin	  membrane	   growth	   and	   that	   mutant	   oligodendrocytes	   must	   take	   up	   cholesterol	   from	  other	   cell	   types,	   e.g.	   astrocytes,	   to	   support	   myelin	   synthesis	   (Saher	   et	   al.,	   2005).	  Oxysterols	  are	  also	  necessary	  for	  brain	  cell	  formation.	  LXR	  deletion	  results	  in	  decreased	  dopaminergic	   neurons	   and	   accumulation	   of	   radial	   glial	   cells	   at	   birth,	   while	   LXR	  activation	  by	  oxysterols	   leads	  to	   increased	  DA	  neurons	   in	  mouse	  embryonic	  stem	  cells	  (Sacchetti	  et	  al.,	  2009).	  	  
4.	  Cholesterol	  and	  Alzheimer’s	  disease	  
	  
4.1	  Alzheimer’s	  disease	  and	  its	  animal	  models	  
	  Alzheimer’s	  disease	  (AD,	  OMIM	  104300)	  is	  the	  most	  common	  cause	  of	  dementia	  among	  elderly	   people.	   The	   major	   pathological	   hallmarks	   of	   AD	   are	   abnormal	   formation	   of	  extracellular	   amyloid β (Aβ)	   plaques	   and	   intracellular	   tau-­‐containing	   neurofibrillary	  tangles	   in	   the	   brain.	   There	   are	   two	   histopathologically	   indistinguishable	   forms	   of	   AD,	  based	   on	   the	   onset	   time	   and	   genetic	   factors.	   The	   rare	   familial	   early-­‐onset	   form	  of	   AD	  (FAD)	  commences	  before	  65	  years	  of	  age,	  typically	  in	  patients	  in	  their	  40s	  or	  50s,	  and	  is	  caused	  by	  mutations	  in	  genes	  encoding	  amyloid	  precursor	  protein	  (APP),	  presenilin	  (PS)	  1	   and	  PS2	   (Borchelt	   et	   al.,	   1996).	   The	  more	   common	   sporadic	   late-­‐onset	  AD	  does	  not	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involve	  mutations	   in	  these	  three	  genes,	  but	  25%	  of	  patients	  with	  this	   form	  of	  AD	  have	  close	   relatives	   with	   dementia,	   suggesting	   that	   there	   exist	   other	   genetic	   factors	   (Bird,	  2005).	   Susceptibility	   to	   AD	   is	   also	   APP	   dose-­‐dependent.	   Down’s	   syndrome	   patients	  bearing	  an	  extra	  chromosome	  21	  (trisomy	  21),	   thereby	  with	  an	  additional	  copy	  of	   the	  
APP	  gene,	  will	  ultimately	  develop	  an	  AD-­‐like	  pathology	  (Rumble	  et	  al.,	  1989).	  	  	  Several	   transgenic	   (TG)	   AD	   mouse	   models	   have	   been	   generated	   to	   understand	   the	  pathological	   mechanism	   of	   AD,	   and	   most	   of	   them	   aim	   for	   accumulated	   brain	   Aβ	   in	  resemblance	  of	  AD.	  Differentially	   targeted	   single-­‐,	   double-­‐,	   or	   triple-­‐TG	  mouse	  models	  have	  been	  established.	  For	  example,	  APP23	  TG	  mice	  expressing	  human	  Swedish	  mutant	  APP	  (APPswe)	  show	  characteristics	  of	  human	  AD,	  i.e.	  prominent	  plaque	  deposition	  with	  a	  fibrillar	  Aβ	  core	  and	  neuronal	  death	  in	  the	  brain	  (Calhoun	  et	  al.,	  1998).	  Double-­‐TG	  mice	  coexpressing	  human	  wild-­‐type	  APP	  and	  FAD-­‐PS1	  mutant	  (M146L,	  A246E,	  or	  dE9)	  have	  been	  developed	  and	  show	  elevated	  Aβ42	  levels	  and	  Aβ42:	  Aβ40	  ratios	  (Borchelt	  et	  al.,	  1996).	   Double-­‐TG	  mice	   coexpressing	   APPswe	   and	   PS1	  mutant	   (A246E	   or	   dE9)	   show	   a	  positive	  correlation	  between	  Aβ42	  elevation	  and	  the	  age	  of	  amyloid	  onset	  (Jankowsky	  et	  al.,	  2004).	  Coexpression	  of	  transforming	  growth	  factor-­‐β1	  in	  APP	  TG	  mice	  that	  develop	  AD-­‐like	  pathology	  accelerates	  the	  deposition	  of	  Aβ	  peptide	  (Wyss-­‐Coray	  et	  al.,	  1997).	  A	  triple-­‐TG	  mouse	  model	   harboring	   PS1M146V,	   APPswe,	   and	   tauP301L	  provides	   insights	   into	  determining	   the	   relationships	   among	   Aβ	   plaque,	   synaptic	   dysfunction,	   and	  neurofibrillary	  tangles	  (Oddo	  et	  al.,	  2003).	  There	  are	  many	  other	  AD	  models	  that	  are	  not	  listed	  here,	  but	  their	  contributions	  to	  basic	  and	  therapeutic	  research	  in	  AD	  are	  valuable.	  	  
4.2	  APP	  family	  proteins	  
	  The	  main	  component	  of	  the	  amyloid	  plaque	  is	  Aβ	  peptide,	  which	  is	  a	  33-­‐43	  amino	  acids	  peptide	  derived	  from	  APP.	  The	  APP	  gene	  was	  first	  identified	  and	  cloned	  to	  chromosome	  21	   in	   1987	   (Kang	   et	   al.,	   1987).	   APP	   is	   a	   type	   I	   transmembrane	   glycoprotein	   that	   is	  detectable	   in	  both	  adult	  and	   fetal	  brain	  and	  numerous	  nonneuronal	   tissues	   in	  humans	  and	   lower	  mammals,	   e.g.	   adrenal	   gland,	   kidney,	   spleen,	   heart,	   and	   liver	   (Selkoe	   et	   al.,	  1988).	  Neuronal	  APP	  is	  much	  more	  of	  a	  695	  amino	  acids	  splicing	  form,	  and	  nonneuronal	  APP	  is	  more	  of	  a	  751	  or	  770	  residue	  form	  (Haass	  et	  al.,	  1991)	  that	  contains	  a	  Kunitz-­‐type	  of	   serine	   protease	   inhibitor	   motif,	   which	   the	   695	   form	   lacks.	   There	   also	   exist	   APP	  orthologs,	   such	  as	  APP-­‐related	  protein	   in	  Caenorhabditis	  elegans	   (Daigle	  and	  Li,	  1993)	  and	  APP-­‐like	  protein	  in	  Drosophila	  (Rosen	  et	  al.,	  1989).	  	  In	  mammals,	  APP	  belongs	   to	   a	  protein	   family	   that	   includes	   two	  other	  members,	  APLP	  (amyloid	   precursor-­‐like	   protein)	   1	   and	   APLP2,	  which	   exhibit	   highly	   conserved	   amino	  acid	   and	   domain	   structure	   homology	   of	   APP.	   However,	   only	   APP	   can	   give	   rise	   to	   the	  formation	   of	   senile	   amyloid	   plaques,	   since	   both	   APLP	   proteins	   lack	   the	   Aβ	   sequence.	  Despite	   the	   sequence	   similarity	   among	   APP	   family	   proteins,	   their	   presence	   in	   tissues	  and	   localization	   in	   cells	   are	   not	   identical	   (Kaden	   et	   al.,	   2009).	   APP	   and	   APLP2	   are	  ubiquitously	   expressed	   in	   the	   brain	   and	   peripheral	   tissues	   (Slunt	   et	   al.,	   1994),	   while	  APLP1	  is	  only	  detected	  in	  the	  brain.	  Live	  cell	  imaging	  shows	  that	  APP	  and	  APLP2	  mainly	  localize	   in	   the	   intracellular	   compartments,	   and	   APLP1	   mostly	   resides	   in	   the	   PM,	  especially	   cell-­‐cell	   contact	   sites,	   thus	   playing	   a	   role	   in	   cell	   adhesion.	   All	   APP	   family	  proteins	  are	  able	  to	  form	  homodimers	  and	  heterodimers	  in	  their	  ectodomain,	  although	  their	   distinct	   localizations	   lead	   to	   different	   degrees	   of	   heterodimerization	   forms.	   The	  homodimerization	   of	   APP	   and	   heterodimerization	   of	   APP	  with	  APLPs	  may	   abolish	   Aβ	  generation	  (Kaden	  et	  al.,	  2008;	  Kaden	  et	  al.,	  2009).	  	  
	  	  	  
	  
21	  
Several	   mouse	   models	   have	   been	   generated	   to	   access	   the	   importance	   of	   APP	   family	  proteins	  in	  vivo.	  Mice	  with	  a	  single-­‐KO	  in	  each	  APP	  family	  protein	  are	  viable.	  APP-­‐/-­‐	  mice	  show	   reactive	   gliosis	   and	   decreased	   locomotor	   activity	   (Zheng	   et	   al.,	   1995).	   APLP1-­‐/-­‐	  mice	   exhibit	   a	   postnatal	   growth	  deficit	   (Heber	   et	   al.,	   2000).	   APLP2-­‐/-­‐	  mice	   are	   normal	  and	   healthy	   (von	   Koch	   et	   al.,	   1997).	   Interestingly,	   each	   single-­‐KO	   doesn’t	   lead	   to	  compensatory	   upregulation	   of	   the	   other	   two	   APP	   family	   members	   (von	   Koch	   et	   al.,	  1997;	   Zheng	   et	   al.,	   1995).	   APLP2-­‐/-­‐/APLP1-­‐/-­‐	   and	   APLP2-­‐/-­‐/APP-­‐/-­‐	  dKO	  mice	  die	   shortly	  after	   birth;	   however,	   the	   APLP1-­‐/-­‐/APP-­‐/-­‐mice	   are	   viable,	   and	   no	   APLP2	   compensation	  was	  observed	  (Heber	  et	  al.,	  2000).	  This	  suggests	  a	  redundancy	  between	  APLP2	  and	  APP	  or	  APLP1,	  and	  APLP2	  performs	  a	  key	  role	  among	  the	  APP	  family	  members.	  As	  expected,	  the	  triple-­‐KO	  mice	  show	  postnatal	  mortality	  (Heber	  et	  al.,	  2000).	  	  In	   other	   model	   organisms,	   APP	   is	   found	   to	   play	   several	   important	   roles	   as	   well.	   For	  instance,	   loss	   of	   the	   APP	   ortholog	   results	   in	   developmental	   lethality	   in	   C.elegans	  (Hornsten	  et	  al.,	  2007).	   In	  D.	  melanogaster,	  the	  APP	  ortholog	  is	  required	  for	  promoting	  axonal	  outgrowth,	  neurite	  branching,	  and	  synapse	  formation	  (Shariati	  and	  De	  Strooper,	  2013).	  	  	  
4.3.	  APP	  processing	  and	  fragments	  
	  APP	   experiences	   complex	   processings	   in	   a	   highly	   regulated	   manner	   and	   generates	  several	  proteolytic	  fragments	  to	  fulfill	  their	  various	  roles	  in	  the	  cell.	  The	  APP	  processing	  is	   directly	   involved	   in	   Alzheimer’s	   pathology,	   which	   may	   provide	   insights	   into	   AD	  diagnosis	  and	  prevention.	  	  	  Newly	   synthesized	   APP	   undergoes	   several	   posttranslational	   modifications:	   N-­‐glycosylation	  in	  the	  ER,	  O-­‐glycosylation	  and	  sulfation	  within	  the	  ectodomain	  in	  the	  Golgi,	  and	   phosphorylation	  within	   the	   cytoplasmic	   domain	   (Lee	   et	   al.,	   2003).	  Mature	  APP	   is	  then	   translocated	   via	   secretory	   vesicles	   to	   the	   PM,	   where	   the	   N-­‐terminal	   ectodomain	  faces	   towards	   the	  extracellular	  milieu	  and	   the	  C-­‐terminal	  domain	   faces	   the	   cytoplasm.	  The	  cell-­‐surface	  APP	  can	  be	  reinternalized	  via	  the	  clathrin-­‐mediated	  endocytic	  pathway,	  dependent	  on	  the	  APP	  C-­‐terminal	  YENPTY	  domain	  as	  a	  signal	  (Perez	  et	  al.,	  1999).	  APP	  can	   also	  be	   covalently	  modified	  by	   Small	  Ubiquitin-­‐like	  Modifier,	   leading	   to	   a	   reduced	  amount	  of	  Aβ	  aggregates	  (Zhang	  and	  Sarge,	  2008).	  	  APP	   is	   subjected	   to	   proteolytic	   cleavages	   during	   or	   after	   the	   posttranslational	  modifications	   in	   the	   secretory	   pathway	   (Figure	   5).	   APP	   is	   constitutively	   cleaved	   in	   a	  non-­‐amyloidogenic	   pathway	   in	   the	   PM	   and	  Golgi	   network	   by	  α-­‐secretase	   (ADAM10,	   a	  member	  of	  A	  Disintegrin	  And	  Metalloproteinase	  family),	  producing	  the	  soluble	  amyloid	  precursor	  protein	   (APPs)	  α	   ectodomain	  and	  C-­‐terminal	   fragment	  C83	   (Lammich	  et	  al.,	  1999).	  Alternatively,	  APP	   can	   go	   through	   the	   amyloidogenic	  pathway	   in	   the	  Golgi	   and	  endosomes,	  where	   it	   is	  cleaved	  by	  β-­‐secretase	  (BACE1)	   into	  APPsβ and	  C99	  (Vassar	  et	  al.,	  1999).	  Both	  C83	  and	  C99	  can	  be	   further	  processed	  by	  γ-­‐secretase	   to	  generate	  P3	  +	  APP	   intracellular	   domain	   (AICD)	   or	   Aβ +	   AICD,	   respectively	   (Chow	   et	   al.,	   2010).	   γ-­‐secretase	   is	   a	   multiprotein	   complex	   consisting	   of	   PS,	   nicastrin,	   anterior	   pharynx-­‐defective	  1,	  and	  PS	  enhancer	  2	   (Kimberly	  et	  al.,	  2003).	  The	   two	  amino	  acids	  shift	  of	  γ-­‐cleavage	  in	  the	  intramembrane	  domain	  of	  APP	  results	  in	  two	  Aβ forms,	  Aβ42	  and	  Aβ40,	  of	  which	  Aβ42	  is	  highly	  amyloidogenic.	  Similarly,	  processing	  of	  APLPs	  also	  occurs	  via	  α-­‐,	  
β-­‐,	  and	  γ-­‐secretases	  as	  APP	  (Eggert	  et	  al.,	  2004).	  The	  cellular	  cholesterol	  level	  negatively	  impacts	   Aβ	   formation,	   while	   the	   levels	   of	   the	   APP	   ectodomains	   remain	   unchanged	  (Simons	   et	   al.,	   1998),	   because	   low	   ER	   cholesterol	   levels	   lead	   to	   decreased	   APP	   β-­‐cleavage	  (Runz	  et	  al.,	  2002).	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  Worth	  mentioning,	  the	  γ-­‐cleavage	  of	  APP	  is	  a	  regulated	  intramembrane	  proteolysis	  (RIP)	  process.	   Other	   than	   APP,	   γ-­‐secretase	   also	   mediates	   cleavage	   of	   a	   number	   of	  transmembrane	  proteins,	  including	  Notch,	  neprilysin,	  LRP,	  and	  many	  others	  (Kopan	  and	  Ilagan,	  2004).	  Interestingly,	  the	  cleavage	  of	  SREBP	  proteins	  is	  also	  an	  RIP,	  although	  the	  enzyme	  responsible	  for	  this	  process	  is	  different	  from	  γ-­‐secretase	  (Tomita	  et	  al.,	  1998).	  
	  
Figure	  5.	  Schematic	  illustration	  of	  APP	  proteolytic	  fragments.	  	  
	  
	  
	  	  The	   N-­‐terminal	   APP	   ectodomains	   APPsα	   and	   APPsβ can	   be	   secreted	   from	   cells	   and	  found	   in	   the	   brain	   and	   cerebrospinal	   fluid	   (Palmert	   et	   al.,	   1989).	   Shedding	   of	   APP	  ectodomains	   can	   be	   enhanced	   by	   TNF-­‐α	   (Slack	   et	   al.,	   2001)	   and	   statin	   via	   the	   Rho-­‐associated	   protein	   kinase	   pathway	   (Pedrini	   et	   al.,	   2005).	   Both	   APP	   ectodomains	   have	  been	   recognized	   in	   several	   physiological	   roles,	   such	   as	   increasing	   epidermal	   growth	  factor	   (EGF)-­‐induced	   proliferation	   of	   subventricular	   zone	   progenitors	   (Caille	   et	   al.,	  2004)	   and	   promoting	   neurite	   outgrowth,	   synaptogenesis,	   and	   cell	   adhesion	   (Mattson,	  1997).	  APPsα knock-­‐in	  grossly	  attenuates	  deficits	  of	  APP	  KO	  mice	  (Ring	  et	  al.,	  2007)	  and	  rescues	   the	  postnatal	   lethality	   of	  APLP2-­‐/-­‐/APP-­‐/-­‐	  dKO	  mice	  despite	  deficits	   in	   synaptic	  transmission	   (Weyer	   et	   al.,	   2011),	   whereas	   APPsβ does	   not	   (Li	   et	   al.,	   2010).	   The	   N-­‐terminal	   of	   APPsβ is	   a	   death	   receptor	   6	   ligand	   for	   triggering	   axonal	   degeneration	   via	  caspase	  6	  during	  trophic	  factor	  loss	  (Nikolaev	  et	  al.,	  2009).	  	  	  Additionally,	   the	   C-­‐terminal	   APP	   fragment	   AICD	   is	   a	   transcriptional	   factor	   in	   gene	  expression	  regulation.	  By	  binding	   to	   the	  nuclear	  adaptor	  protein	  Fe65,	  AICD	   is	  able	   to	  translocate	   to	   the	   nucleus	   and	   form	   a	   multimeric	   complex	   with	   the	   histone	  acetyltransferase	   Tip60	   (Cao	   and	   Sudhof,	   2001).	   In	   this	   way,	   AICD	   regulates	   the	  transcription	  of	  BACE1	  and	  APP	  to	  stimulate	  its	  own	  production	  (von	  Rotz	  et	  al.,	  2004).	  AICD	   also	   activates	   glycogen	   synthase	   kinase	   3β	   (GSK3β),	   which	   catalyzes	  hyperphosphorylation	   of	   tau	   protein	   in	   the	   formation	   of	   neurofibrillary	   tangles,	  contributing	   to	   AD	   pathogenesis	   (Ghosal	   et	   al.,	   2009).	   Furthermore,	   AICD	   represses	  LRP1	   transcription	   (Liu	  et	  al.,	  2007),	  although	   this	   finding	  could	  not	  be	  reproduced	   in	  another	   study	   (Tamboli	   et	   al.,	   2008).	   Similarly,	   ICDs	   derived	   from	   APLPs	   can	   also	   be	  stabilized	  by	  Fe65	  and	  translocated	  to	  the	  nucleus.	  The	  degradation	  of	  the	  ICDs	  of	  APP	  and	  APLPs	  is	  mediated	  by	  insulin-­‐degrading	  enzyme	  (IDE)	  (Walsh	  et	  al.,	  2003).	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Interestingly,	  Aβ	  not	  only	  acts	  as	   the	  pathological	   factor	  of	  AD,	  but	  also	  plays	  a	  role	   in	  cellular	   regulations.	   Aβ	   inhibits	   APP	   expression	   by	   decreasing	   the	   AICD	   level	   and	  complex	   formation	   with	   Fe65.	   Aβ40	   inhibits	   HMGR	   activity	   and	   downregulates	  cholesterol	   synthesis,	   whereas	   Aβ42	   activates	   sphingomyelinases	   and	   reduces	   the	  sphingomyelin	  level	  (Grimm	  et	  al.,	  2005).	  	  	  Preclearance	   of	   Aβ	   is	   especially	   important	   in	   the	   brain	   to	   prevent	   Aβ	   aggregation.	  Transport	   of	   Aβ	   across	   the	   BBB	   may	   involve	   different	   receptors.	   The	   receptor	   for	  advanced	  glycation	  end	  products	  takes	  up	  Aβ	  from	  the	  periphery	  to	  the	  brain	  (Deane	  et	  al.,	  2009).	  On	  the	  other	  hand,	  LRP1	  and	  VLDLr	  mediate	  Aβ efflux	  to	  the	  blood,	  therefore	  soluble	   LRP1	   is	   considered	   as	   a	   plasma	   Aβ	   sink	   that	   sequesters	   Aβ	   for	   degradation	  (Zlokovic	  et	  al.,	  2010).	  Aβ	  degradation	  was	  enabled	  by	  several	  mechanisms.	  Neprilysin	  is	  a	   key	   Aβ-­‐degrading	  metalloprotease	   (Iwata	   et	   al.,	   2001)	   that	   can	   be	   transcriptionally	  regulated	   by	   PS	   and	   AICD	   (Pardossi-­‐Piquard	   et	   al.,	   2005).	   IDE	   and	   angiotensin-­‐converting	   enzyme	   are	   also	   candidate	   peptidases	   for	   Aβ	   degradation	   (Carson	   and	  Turner,	  2002).	  Furthermore,	  the	  level	  of	  ApoE	  lipidation	  may	  also	  determine	  the	  degree	  of	   Aβ	   clearance,	   since	   delipidated	   ApoE	   exhibits	   a	   decreased	   affinity	   for	   Aβ	   peptides	  (Tokuda	  et	  al.,	  2000).	  	  
4.4	  Links	  between	  cholesterol	  and	  Alzheimer’s	  disease	  
	  ApoE	  is	  a	  major	  cholesterol	  carrier	  protein	  that	  includes	  three	  isoforms:	  ApoE	  ɛ2	  (1-­‐5%),	  ApoE	  ɛ3	  (50-­‐90%),	  and	  ApoE	  ɛ4	  (5-­‐35%).	  ApoE	  ɛ4	  was	  identified	  as	  a	  risk	  factor	  for	  AD	  (Corder	   et	   al.,	   1993),	   and	   additional	   ApoE	   leads	   to	   Aβ	   filament	   (formed	   by	   Aβ	   lateral	  aggregation)	   formation	   (Ma	  et	   al.,	   1994).	  Many	  experimental	   investigations	  have	  been	  carried	   out	   in	   attempts	   to	   explain	   the	   isoform-­‐specific	   effects	   of	   ApoE	   ɛ4	   in	   AD	  susceptibility,	  and	  they	  have	  shown	  that	  ApoE	  ɛ4	  may	  play	  multiple	  roles	  in	  the	  process.	  For	   instance,	   since	   ApoE	   ɛ4	   is	   structurally	   different	   from	   other	   ApoE	   isoforms,	   it	  interacts	  with	  Aβ	  at	  a	  lower	  affinity,	  thus	  clearing	  Aβ	  from	  the	  brain	  less	  efficiently	  (Kim	  et	   al.,	   2009).	   ApoE	   ɛ4	   also	   stimulates	   proinflammatory	   cytokines,	   while	   ApoE	   ɛ3	  suppresses	   inflammatory	   responses	   (Lynch	  et	  al.,	  2003).	  Moreover,	  ApoE	  ɛ4	   increases	  BBB	   leakage	   (Bell	   et	   al.,	   2012),	   sequesters	   glutamate	   receptors,	   and	   impairs	   synaptic	  activity	  (Chen	  et	  al.,	  2010),	  leading	  to	  undermined	  CNS	  functioning	  in	  AD.	  	  	  Cellular	  cholesterol	  distribution	  and	  content	  are	  closely	  associated	  with	  Aβ generation,	  which	   may	   eventually	   give	   rise	   to	   AD	   pathology.	   β-­‐cleavage	   of	   APP	   occurs	  predominantly	   in	   cholesterol-­‐rich	   lipid	   rafts	   of	   the	   cell	   membrane,	   and	   depletion	   of	  cholesterol	   inhibits	   Aβ	   generation	   (Cordy	   et	   al.,	   2003).	   On	   the	   other	   hand,	   the	   non-­‐amyloidogenic	   α-­‐processing	   of	   APP	   mainly	   occurs	   in	   cholesterol-­‐poor	   membranes	  (Kojro	   et	   al.,	   2001).	   Since	   cholesterol	   helps	   determine	   the	   biophysical	   properties	   of	  cellular	  membranes	  and	  membrane-­‐associated	  protein	  activity,	   it	   is	  not	  surprising	  that	  it	   also	   affects	   APP	   processing,	   especially	   when	  α-­‐	   and	   β-­‐cleavage	   are	   juxtamembrane	  events	   and	   γ-­‐cleavage	   is	   intramembrane,	   not	   to	  mention	   that	   the	   γ-­‐secretase	   complex	  and	   the	   substrate	   APP	   itself	   are	   both	   transmembrane	   proteins.	   Abnormal	   cholesterol	  accumulation	  in	   late	  endosomes	  greatly	  enhanced  γ-­‐secretase	  activity	  and	  Aβ	   levels	   in	  the	  NPC	  mouse	  brain	  (Burns	  et	  al.,	  2003).	  In	  contrast,	  low	  cholesterol	  levels	  are	  found	  to	  inhibit	  β-­‐	  and	  γ-­‐secretase	   independently	  (Grimm	  et	  al.,	  2008).	  Treatment	  with	  statin,	  a	  cholesterol-­‐lowering	   drug,	   also	   strongly	   reduces	   the	   Aβ	   level	   in	   both	   primary	   culture	  and	  guinea	  pigs	  (Fassbender	  et	  al.,	  2001).	  Recently,	  a	  nuclear	  magnetic	  resonance	  study	  of	   C99	   structure	   showed	   that	   its	   membrane-­‐buried	   GXXXG	   motif,	   which	   drives	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dimerization	  of	  C99,	  is	  crutial	  for	  cholesterol	  binding.	  The	  C99-­‐cholesterol	  binding	  may	  enhance	  the	  γ-­‐cleavage	  and	  reduce	  α-­‐cleavage	  of	  C99	  (Barrett	  et	  al.,	  2012).	  Interestingly,	  an	   in	   vivo	   study	   using	   a	   cholesterol	   24-­‐hydroxylase	   KO	   /	   APPswe	   TG	   mouse	   model	  detected	  modestly	   reduced	  Aβ	   levels,	  but	  not	  Aβ	   plaque,	   in	   the	  hippocampus	   (Halford	  and	   Russell,	   2009),	   suggesting	   a	   delicate	   balance	   between	   cholesterol	   levels	   and	   AD	  pathogenesis	  that	  needs	  to	  be	  investigated	  further.	  	  As	  evidence	  points	  towards	  that	  cholesterol	  directing	  AD	  pathogenesis,	  a	  recent	  study	  of	  AD	   patient	   plasma	   showed	   significantly	   decreased	   desmosterol	   and	   desmosterol:	  cholesterol	  ratio,	  compared	  with	  healthy	  elderly	  patients.	  This	  suggests	  an	   imbalanced	  cholesterol	  metabolism	   in	  AD,	  and	  plasma	  desmosterol	   level	   to	  be	  a	  biomarker	   for	  AD	  diagnosis	  (Sato	  et	  al.,	  2011).	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Aims of the Study 	  The	  aim	  here	  was	  to	  examine	  the	  metabolic	   fate	  of	  cholesterol	  as	  well	  as	   its	  precursor	  sterols	   and	   metabolite	   steroid	   hormone	   DHEA,	   and	   to	   determine	   how	   these	   are	  regulated.	  The	  individual	  aims	  for	  each	  study	  are	  listed	  below:	  	  In	   the	   first	   study,	   we	   aimed	   to	   investigate	   the	   uptake,	   hydrolysis,	   and	  metabolism	   of	  DHEA-­‐FAE-­‐LDL	   in	   cells.	   Although	   relatively	   high	   concentrations	   of	   DHEA-­‐FAE	  associated	  with	  LDL	  have	  been	  found	  in	  blood,	  how	  DHEA-­‐FAE-­‐LDL	  is	  processed	  in	  cells	  was	   still	   elusive.	   	   Since	   the	   processing	   of	   cholesterol-­‐FAE-­‐LDL	   has	   been	   exhaustively	  studied,	   we	   compared	   the	   characteristic	   aspects	   of	   it,	   e.g.	   LDL	   uptake	   by	   LDLr	   and	  hydrolysis	   by	   lysosomal	   LAL,	   with	   those	   of	   DHEA-­‐FAE-­‐LDL	   to	   examine	   their	   unique	  kinetics.	  	  The	   aim	   of	   the	   second	   study	   was	   to	   explore	   the	   cause	   for	   the	   rapid	   accumulation	   of	  desmosterol	   during	   brain	   development	   and	   the	   functions	   that	   accumulating	  desmosterol	  may	  serve.	  Based	  on	   literatures	   that	  described	  desmosterol	  accumulation	  and	  addressed	   its	  physiological	   roles,	   together	  with	  our	  own	  experimental	   results,	  we	  proposed	   the	   potential	   cause	   and	   effects	   of	   the	   accumulating	   desmosterol	   in	   the	  developing	  brain.	  	  In	  the	  third	  study,	  we	  aimed	  to	  define	  the	  physiological	  role	  of	  APP	  and	  its	  proteolytic	  fragments	   in	   regulating	   cholesterol	   metabolism.	   APP-­‐derived	   Aβ	   and	   AICD	   inhibit	  cholesterol	   synthesis	   and	   related	   pathways;	   however,	   these	   studies	   were	   mostly	  conducted	  using	  mouse	  models,	  hence	  the	  results	  may	  elude	  the	  direct	  impact	  of	  APP.	  In	  our	  study,	  we	  used	  cell	  lines	  of	  astrocytic	  and	  hepatic	  origins	  as	  well	  as	  primary	  human	  fibroblasts,	   investigated	  the	  cholesterol	  synthesis	  pathway	  by	  transiently	  manipulating	  the	   levels	   of	   APP	   and	   its	   processing	   products,	   dissected	   the	   different	   roles	   of	   these	  products,	  and	  provided	  the	  underlying	  regulatory	  mechanism.	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Materials and Methods 	  	  	  
Method	   Publication	  	  Cell	  culture	   	  I,	  II,	  III	  Cell	  transfection	   I,	  II,	  III	  Protein	  determination	  	   I,	  II,	  III	  	  SDS-­‐PAGE	  and	  Western	  blotting	   I,	  II,	  III	  Quantification	  of	  Western	  blots	   I,	  III	  [3H]-­‐cholesteryl	  oleate	  labeling	   I	  Lipid	  extraction	   I,	  II,	  III	  Thin-­‐layer	  chromatography	   I,	  III	  Cholesterol	  determination	   I,	  III	  DNA	  cloning	   III	  DNA	  mutagenesis	  	   III	  Nuclear	  fractionation	   III	  Luciferase	  assay	   III	  Fluorescent	  staining	  and	  microscopy	   III	  [3H]-­‐acetate	  labeling	   III	  Ag+	  high-­‐performance	  liquid	  chromatography	   III	  High-­‐performance	  thin-­‐layer	  chromatography	   II,	  III	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1.	  Cell	  culture	  and	  transient	  transfections	  (I,	  II,	  III)	  
	  Cells	  were	   from	  ATCC	  except	   indicated	  otherwise.	  HeLa	   (I)	  and	  HepG2	  (III)	   cells	  were	  cultured	   in	  Dulbecco's	  modified	   eagle	  medium	   (DMEM)	   supplemented	  with	   10%	   fetal	  bovine	   serum	   (FBS),	   100	   U/ml	   penicillin	   and	   streptomycin,	   and	   2	   mM	   L-­‐glutamine.	  U251MG	  cells	  (III)	  were	  cultured	  in	  RPMI	  medium	  with	  the	  same	  supplements	  as	  above.	  Human	   control/Wolman	   fibroblasts	   (I)	   were	   cultured	   in	   Eagle’s	   minimum	   essential	  medium	  (EMEM)	  with	  10%	  FBS,	  10	  mM	  HEPES	  pH	  7.4,	  and	  penicillin,	  streptomycin,	  L-­‐glutamine	  as	  above.	  Human	  control	  fibroblasts	  and	  APPDp	  patient	  fibroblasts	  (provided	  by	   Anne	   Remes,	   Kuopio	   University	   Hospital)	   derived	   from	   a	   Finnish	   AD	   family	   	   (III)	  were	   cultured	   in	   DMEM	   with	   15%	   FBS	   and	   penicillin,	   streptomycin,	   L-­‐glutamine	   as	  above.	   For	   experiments,	   the	   cells	   were	   also	   grown	   in	   serum-­‐free	   medium	   or	   5%	  lipoprotein-­‐deficient	  serum	  (LPDS)	  medium	  as	  indicated.	  	  To	  introduce	  small	  interfering	  RNA	  (siRNA)	  oligos	  (Biomers)	  and/or	  plasmid	  constructs,	  Lipofectamine	   2000	   (Invitrogen)	   was	   used	   for	   HeLa,	   U251MG,	   and	   HepG2	   cells	  according	  to	  the	  manufacturer’s	  instructions.	  GL2	  siRNA	  oligos	  were	  used	  as	  controls	  in	  all	  transfections,	  except	  in	  the	  luciferase	  assays	  where	  AllStars	  (Sigma)	  was	  used.	  After	  a	  4-­‐h	   transfection	   in	   complete	  medium,	   the	   cells	  were	  washed	  with	  phosphate-­‐buffered	  saline	  (PBS)	  and	  cultivated	  in	  serum-­‐free	  medium	  for	  20	  h,	  unless	  otherwise	   indicated	  in	   the	   experiments.	   To	   transfect	   the	   siRNA	   oligos	   in	   human	   fibroblasts,	   Ribocellin	  (BioCellChallenge)	  was	  used	  according	  to	  the	  manufacturer’s	  instructions.	  	  
2.	  Immunoblotting	  (I,	  II,	  III)	  
	  The	  cell	  samples	  were	  lysed	  in	  1%	  NP40	  [except	  for	  SREBP2	  and	  phospho-­‐GSK3β	  serine	  9	  (S9)	  blots]	  with	  protease	  inhibitors	  chymostatin,	  leupeptin,	  aprotinin,	  and	  pepstatin	  at	  25	  μg/ml	  each.	  The	  amount	  of	  proteins	  in	  the	  lysate	  was	  measured	  by	  Protein	  Assay	  kit	  (Bio-­‐Rad).	  	  For	  mature	  SREBP2	  blotting	  from	  nuclear	  fractionation,	   the	  cells	  were	  treated	  with	  10	  
µM	  MG132	   for	  1	  h	  before	  harvesting	  and	   lysed	   in	  sodium	  dodecyl	  sulfate	   (SDS)	  buffer	  containing	   protease	   inhibitors	   (Espenshade	   et	   al.,	   1999).	   The	   cell	   samples	   were	   then	  prepared	   as	   described	   (DeBose-­‐Boyd	   et	   al.,	   1999)	   with	   modifications.	   Cells	   from	  duplicate	  60-­‐mm	  dishes	  were	  harvested	  by	  trypsinizing	  and	  pooled.	  The	  cells	  were	  then	  suspended	   in	   400	  µl	   of	   buffer	   A	   (10	  mM	  HEPES-­‐KOH	   at	   pH	   7.4,	   10	  mM	  KCl,	   1.5	  mM	  MgCl2,	   1	   mM	   sodium	   EDTA,	   1	   mM	   sodium	   EGTA,	   250	   mM	   sucrose)	   with	   protease	  inhibitors	  and	  swollen	  on	  ice	  for	  30	  min.	  The	  swollen	  cells	  were	  passed	  through	  a	  22.5-­‐gauge	  needle	  about	  30	  times	  until	  a	  clear	  separation	  of	  the	  intact	  nucleus	  from	  the	  rest	  of	   the	   cell	  membranes	   appeared.	   The	   crude	   cell	   fractions	  were	   centrifuged	   at	   1000-­‐g	  (3300	  rpm	  for	  an	  8.5-­‐cm	  radius)	  at	  4	  °C	  for	  7	  min.	  The	  pellet	  from	  the	  1000-­‐g	  spin	  was	  resuspended	   in	   30	  µl	   of	   buffer	   B	   (20	  mM	  HEPES-­‐KOH	   at	   pH	   7.6,	   2.5%	   (v/v)	   glycerol,	  0.42	  M	  NaCl,	   1.5	  mM	  MgCl2,	   1	  mM	   sodium	  EDTA,	   1	  mM	   sodium	  EGTA)	  with	   protease	  inhibitors,	  rotated	  at	  4	  °C	  for	  1	  h,	  and	  centrifuged	  at	  100	  000	  g	  (50	  000	  rpm)	  for	  30	  min	  at	  4	  °C	  in	  a	  TLA	  100.2	  rotor	  (Beckman).	  The	  supernatant	  from	  this	  spin	  was	  designated	  as	  the	  nuclear	  fraction.	  The	  supernatant	  from	  the	  1000-­‐g	  spin	  was	  used	  to	  prepare	  the	  membrane	  fraction	  by	  centrifuging	  at	  20	  000	  g	  (22	  000	  rpm)	  for	  15	  min	  at	  4	  °C	  in	  a	  TLA	  100.2	   rotor.	   The	   pellet	  was	   dissolved	   in	   30	   ul	   of	   SDS	   lysis	   buffer	   (10	  mM	  Tris-­‐HCl	   at	  pH6.8,	  0.1	  M	  NaCl,	  1%	  SDS,	  1	  mM	  EDTA,	  1	  mM	  EGTA)	  with	  protease	  inhibitors	  and	  used	  as	  the	  membrane	  fraction.	  For	  precursor	  SREBP2	  blotting	  from	  the	  total	  cell	  lysates,	  the	  samples	  were	  lysed	  in	  SDS-­‐buffer	  as	  above.	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For	   APP	   ectodomain	   blotting,	   the	   proteins	   in	   the	   conditioned	   medium	   were	   1:20	  concentrated	   by	   using	   Amicon	   Ultra	   30kDa	   spin	   column	   (Millipore)	   and	   the	  concentrates	  were	  subjected	  to	  analysis.	  	  	  The	  proteins	  were	  separated	  on	  6-­‐10%	  SDS-­‐polyacrylamide	  gel	  electrophoresis	  (PAGE)	  gels,	   transferred	   to	   Hybond-­‐C	   Extra	   membrane,	   stained	   with	   Ponceau	   S	   (Bio-­‐Rad),	  blocked	   with	   defatted	   dry	   milk	   in	   Tris-­‐buffered	   saline	   (TBS)	   with	   0.1%	   Tween-­‐20	  (Sigma),	   and	   immunoblotted	   with	   indicated	   primary	   antibodies	   and	   horseradish	  peroxidase	   (HRP)-­‐conjugated	   secondary	   antibodies,	   followed	   by	   enhanced	  chemiluminescence	   detection.	   Anti-­‐β-­‐tubulin	   and	   anti-­‐Sp3	   antibodies	   were	   used	   as	  loading	  controls	  for	  the	  total	  cell	  lysates	  and	  nuclear	  fraction,	  respectively.	  	  	  For	  phospho-­‐GSK3β	  (S9)	  blotting,	  the	  cells	  were	  lysed	  in	  PBS	  containing	  1%	  SDS,	  5	  mM	  EDTA,	   protease	   inhibitors	   as	   above	   and	   phosphatase	   inhibitors	   (5	   mM	   activated	   Na-­‐orthovanadate,	   25	   mM	   NaF).	   The	   proteins	   were	   separated	   on	   10%	   SDS-­‐PAGE	   gels,	  transferred	  to	  Hybond-­‐C	  Extra	  membranes,	  stained	  with	  ProAct	  (Amresco),	  blocked	  and	  incubated	   with	   anti-­‐phospho-­‐GSK3β	   (S9)	   using	   the	   Odyssey	   system	   (LI-­‐COR).	   The	  intensities	  of	  the	  densitometric	  scanning	  of	  specific	  bands	  were	  quantified	  using	  ImageJ	  software	  (National	  Institutes	  of	  Health,	  USA).	  	  
Table	  1.	  Antibodies	  and	  sources.	  	  Antibody	   Source	   Study	  Mouse	  anti-­‐LAL	   Abcam	  (ab36597)	   I	  Mouse	  anti-­‐actin	  	   Sigma	  (A4700)	   I	  Rabbit	  anti-­‐DHCR24	   Proteintech	  (10471-­‐1-­‐AP)	   II	  Mouse	  anti-­‐V5	   Invitrogen	  (R960-­‐25)	   II	  Mouse	  anti-­‐β-­‐tubulin	   Sigma	  (T4026)	   II,	  III	  Rabbit	  anti-­‐ABCA1	   Novus	  (NB	  400-­‐105)	   II	  Mouse	  anti-­‐human	  EEA1	   BD Transduction 
Laboratories (610457)	   III	  Rabbit	  anti-­‐APP	  C-­‐terminal	  	   Sigma	  (A8717)	   III	  Mouse	  anti-­‐APP	  N-­‐terminal	  	   Millipore	  (clone	  22C11)	   III	  Mouse	  anti-­‐SREBP2	  	   BD	  Biosciences	  (557037)	   III	  Rabbit	  anti-­‐HMGR	  	   Abcam	  (ab98018)	   III	  Rabbit	  anti-­‐LDLr	  	   Fitzgerald	  Industries	  International	  (20R/LR002)	   III	  Mouse	  anti-­‐CYP51	  	   Abnova	  (H00001595-­‐A01)	   III	  Rabbit	  anti-­‐phospho	  GSK3β	  (S9)	   Abcam	  ab75814	   III	  Goat	  anti-­‐mouse	  IgG	  HRP	   Bio-­‐Rad	  (1706516)	   I,	  II,	  III	  Goat	  anti-­‐rabbit	  IgG	  HRP	   Bio-­‐Rad	  (1706515)	   I,	  II,	  III	  	  
3.	  Radiolabeling	  of	  cells	  (I,	  III)	  	  To	  prepare	  [3H]-­‐cholesteryl-­‐FAE-­‐LDL,	  a	  40-­‐mCi	  concentration	  of	  [3H]-­‐cholesteryl	  oleate	  per	   mg	   LDL	   was	   dried	   under	   N2	   flow	   and	   redissolved	   in	   dimethyl	   sulfoxide	   (DMSO)	  (10%	  of	  final	  volume).	  The	  solution	  was	  vortexed	  for	  1	  min	  and	  mixed	  with	  LDL	  for	  2	  h	  at	  40	  °C.	  The	  mixture	  was	  dialyzed	  against	  5	   l	  dialysis	  buffer	  with	  150	  mM	  NaCl	  and	  1	  mM	  EDTA,	  pH	  7.4	  four	  times,	  12	  h	  each.	  	  
	  To	  label	  the	  HeLa	  cells	  and	  human	  fibroblasts	  with	  [3H]-­‐cholesterol-­‐LDL	  and	  [3H]-­‐DHEA-­‐LDL,	  the	  cells	  were	  grown	  for	  4	  days	  in	  LPDS	  medium	  before	  the	  experiments.	  The	  [3H]-­‐
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cholesterol-­‐LDL	   or	   [3H]-­‐DHEA-­‐LDL	   (50	   µg/ml)	   was	   added	   to	   the	   medium	   and	   pulse-­‐labeled	  for	  6	  h	  for	  HeLa	  cells	  or	  8	  h	  for	  fibroblasts.	  After	  washes	  with	  PBS,	  the	  cells	  were	  chased	  in	  serum-­‐free	  medium	  for	  14-­‐24	  h	  (HeLa)	  or	  24-­‐48	  h	  (fibroblasts).	  To	  label	  the	  U251MG	  cells	  with	  [3H]-­‐acetate,	  a	  20-­‐µCi	  final	  concentration	  of	  [3H]-­‐acetate	  was	  added	  in	  serum-­‐free	  medium	  for	  2-­‐h	  pulse-­‐labeling	  at	  37	  °C,	  followed	  by	  a	  1-­‐h	  chase	  at	  37	  °C	  in	  the	  presence	  of	  2.5	  mM	  mevalonate	  and	  10	  µM	   lovastatin.	  For	   [3H]-­‐acetate	   labeling	   in	  HepG2	   cells,	   only	   15-­‐min	   pulse-­‐labeling	   was	   performed	   due	   to	   its	   fast	   turnaround	   in	  these	  cells.	  	  
4.	  Lipid	  extraction	  and	  analysis	  (I,	  II,	  III)	  
	  The	  lipids	  were	  extracted	  from	  the	  cell	  or	  tissue	  samples	  as	   in	  (Bligh	  and	  Dyer,	  1959).	  The	   samples	   were	   scraped	   and	   suspended	   or	   homogenized	   in	   2%	   NaCl,	   and	   aliquots	  were	  taken	  for	  protein	  determination	  (Lowry	  et	  al.,	  1951).	  To	  extract,	  2	  ml	  of	  methanol	  and	   1	   ml	   of	   chloroform	   were	   added	   to	   the	   800	   µl	   suspension	   and	   vortexed,	   then	  centrifuged	  at	  4	  °C,	  2500	  rpm	  for	  10	  min	  to	  pellet	  the	  precipitated	  proteins.	  Chloroform	  and	   H2O	   (1ml	   each)	   were	   added	   to	   the	   upper	   phase	   and	   preceded	   with	   vortex	   and	  centrifugation.	  The	  lower	  organic	  phase	  contained	  the	  lipids	  for	  further	  use.	  	  	  To	   quantify	   the	   radiolabeled	   sterols,	   the	   lipid	   extracts	   were	   resolved	   with	   thin-­‐layer	  chromatography	  (TLC).	  The	  lipids	  were	  applied	  to	  a	  silica	  plate	  with	  the	  corresponding	  standards	  and	  then	  scraped	  and	  counted	  in	  the	  scintillation	  counter.	  	  To	   quantify	   the	   unlabeled	   sterol	  mass,	   high-­‐performance	  TLC	   (HPTLC)	  was	   used.	   The	  lipids	   were	   applied	   to	   the	   silica	   plate	   by	   a	   CAMAG	   machine	   with	   the	   corresponding	  standards.	  The	  plate	  was	   then	  stained	  by	  a	  3%	  copper	  sulfate	  +	  8%	  phosphorous	  acid	  solution,	  and	  charred	  at	  180	  °C	  for	  5	  min.	  The	  densitometry	  of	  the	  visualized	  sterols	  was	  quantified	  using	  ImageJ.	  	  To	  obtain	  high	  resolution	  of	  each	  sterol,	  the	  lipids	  were	  separated	  by	  high-­‐performance	  liquid	   chromatography	   (HPLC).	   Following	   the	   TLC,	   the	   lipids	   were	   further	   extracted	  from	   the	   silica	   and	   injected	   into	   the	   HPLC	   machine.	   The	   sterols	   were	   eluted	   in	   the	  column:	   the	   unlabeled	   sterols	   were	   quantified	   by	   their	   peak	   area	   compared	  with	   the	  standards,	   the	   radiolabeled	   sterols	   were	   collected	   in	   scintillation	   tubes	   at	   the	  appropriate	  time	  points	  according	  to	  those	  of	  the	  standards,	  and	  the	  radioactivities	  were	  measured	  in	  the	  scintillation	  counter.	  	  	  The	   mobile	   phase	   for	   separating	   the	   FC,	   CE	   and	   triacylglycerides	   was	   hexane:diethyl	  ether:acetic	  acid	  80:20:1;	  the	  solvent	  for	  separation	  of	  the	  cholesterol	  and	  other	  sterols	  was	  petroleum	  ether:diethyl	  ether:acetic	  acid	  60:40:1.	  	  
	  The	  total	  cholesterol	  content	  was	  measured	  with	  an	  Amplex	  Red	  kit	  (Molecular	  Probes).	  	  
5.	  DNA	  and	  cloning	  and	  mutagenesis	  (III)	  
	  Wild-­‐type	   human	   APP(695)/pCMV	   and	   APP(695)M596V/pCMV	   constructs	   were	   from	  Dr.	  Dennis	  Selkoe	  (Harvard	  Medical	  School	  Center	   for	  Neurologic	  Diseases	  &	  Women's	  Hospital,	   USA).	   APP-­‐KKAA/pcDNA3	   was	   from	   Dr.	   Henri	   Huttunen	   (University	   of	  Helsinki).	   Human	   APP-­‐C59/pcDNA4	   was	   from	   Dr.	   Frédéric	   Checler	   (Institut	   de	  Pharmacologie	  Moléculaire	   et	   Cellulaire	   Centre,	  National	   de	   la	   Recherche	   Scientifique,	  France).	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The	  APP-­‐C83	  and	  APP-­‐C99	  complementary	  DNAs	  (cDNAs)	  were	  cloned	  from	  wild-­‐type	  human	   APP(695)/pCMV	   construct	   into	   pcDNA3	   and	   pCR3.1	   vectors	   as	   HindIII-­‐EcoRI	  and	  NheI-­‐NotI	  fragments,	  respectively.	  	  	  Point	  mutagenesis	   of	   a	   cDNA	   fragment	   in	   the	   expressing	   vector	  was	   achieved	   using	   a	  Phusion	   Site-­‐Directed	   Mutagenesis	   Kit	   (Thermo).	   The	   point	   mutation	   constructs	   of	  human	   APP(695)-­‐F615P/pCMV	   and	   APP-­‐C99F615P/pCR3.1	   were	   mutagenized	   from	  APP(695)/pCMV	  and	  APP-­‐C99/pCR3.1,	  respectively.	  	  	  	  
6.	  Luciferase	  assay	  (III)	  	  The	   LDLr	   promoter-­‐driven	   Firefly	   luciferase	   activity	   was	   determined	   with	   the	   Dual-­‐Luciferase	   Reporter	   Assay	   system	   (Promega).	   The	   LDLr-­‐Firefly-­‐Luc	   and	   Renilla-­‐Luc	  plasmids	  were	   transfected	   for	   24	   h	   (or	   cotransfected	  with	   siRNAs)	   and	   the	   luciferase	  activities	  measured	   on	   a	   luminometer	   (Promega).	   The	   relative	   LDLr-­‐Firefly	   luciferase	  activity	  was	  calculated	  as	  the	  ratio	  of	  Firefly	  to	  Renilla	  luciferase	  activity.	  	  	  
7.	  Immunocytochemistry,	  microscopy,	  and	  image	  analysis	  (III)	  	  To	   fix	   cells,	   the	   cells	  were	   incubated	   in	   4%	  paraformaldehyde	   (PFA)	  dissolved	   in	   250	  mM	   HEPES	   including	   100	   µM	   MgCl2	   and	   100	   µM	   CaCl2	   for	   30	   min,	   followed	   by	  quenching	  in	  50	  mM	  NH4Cl	  to	  avoid	  autofluorescence	  from	  the	  PFA.	  	  	  For	   α-­‐early	   endosomal	   antigen	   1	   (α-­‐EEA1)	   antibody	   staining,	   a	   5-­‐min	   incubation	   in	  0.1%	  Triton	  X-­‐100	  was	  used	   to	   permeablize	   the	   fibroblasts,	   and	   a	   30-­‐min	  blocking	   in	  10%	   FBS	   at	   37	   °C	   was	   performed	   next.	   The	   cells	   were	   then	   incubated	   with	   primary	  antibody	  in	  10%	  FBS	  at	  37	  °C	  for	  1	  h.	  After	  extensive	  washes,	  the	  cells	  were	  incubated	  with	  secondary	  antibody	  in	  10%	  FBS	  at	  37	  °C	  for	  30	  min.	  The	  cells	  were	  mounted	  using	  Mowiol	  and	  1,4,	  diazobicyclo-­‐(2.2.2)	  octane	  (DABCO).	  	  For	  Dil-­‐LDL	  uptake,	  the	  cells	  were	  grown	  on	  coverslips	  in	  serum-­‐free	  medium	  overnight	  before	  10	  µg/ml	  Dil-­‐LDL	  was	  added	  to	  the	  HepG2	  for	  15-­‐min	  or	  to	  the	  fibroblasts	  for	  90-­‐min	   incubation	   at	   37	   °C.	   The	   cells	   ware	   PFA-­‐fixed	   and	   4',6-­‐diamidino-­‐2-­‐phenylindole (DAPI)-­‐stained	  for	  cell	  number	  quantification.	   	  The	  coverslips	  were	  examined	  using	  an	  Olympus	  Provis	  microscope	  with	  a	  DP71	  camera,	  and	   the	  mages	   were	   acquired	   by	   Cell^A	   software	   (Olympus).	   The	   EEA1	   images	   were	  analyzed	  using	   Image-­‐Pro	  Plus	  software	   (Media	  Cybernetics)	   for	  particle	  counting	  and	  size	   analysis,	   and	   the	   Dil-­‐LDL	   images	   using	   ImageJ	   for	   fluorescence	   intensity	  measurement	  and	  cell	  counting.	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Results and Discussion 
	  
1.	  Role	  of	  lysosomal	  acid	  lipase	  in	  the	  metabolism	  of	  DHEA-­‐FAE-­‐LDL	  	  	  
1.1	  DHEA-­‐FAE-­‐LDL	  uptake	  via	  the	  LDL	  receptor	  	  Considering	  that	  the	  amount	  of	  inert	  DHEA-­‐FAE	  is	  ~50%	  of	  that	  of	  active	  free	  DHEA	  and	  ~50%	  of	  DHEA-­‐FAE	  is	  associated	  with	  LDL	  particles	  in	  the	  circulation,	  it	  is	  important	  to	  understand	   how	   cells	   take	   up	   these	   circulating	   DHEA-­‐FAE-­‐LDLs	   and	   utilize	   them	   to	  produce	   physiologically	   active	   steroids,	   especially	   when	   the	   DHEA-­‐FAE	   proportion	  increases	  with	  age.	  	  To	  study	   the	  cellular	  metabolism	  of	  DHEA-­‐FAE-­‐LDL,	  we	   first	   investigated	   the	  route	  by	  which	  it	  enters	  cells.	   It	  has	  long	  been	  known	  that	  LDLr	  mediates	  the	  cellular	  uptake	  of	  cholesteryl-­‐FAE-­‐LDL;	  therefore,	  we	  tested	  whether	  LDLr	  plays	  a	  role	  in	  DHEA-­‐FAE-­‐LDL	  internalization.	  HeLa	   cells	  were	   incubated	  with	   [3H]-­‐DHEA-­‐FAE-­‐LDL	   in	   the	   absence	  or	  presence	   of	   a	   50-­‐fold	   excess	   of	   unlabeled	   LDL	   for	   6	   h,	   and	   the	   cells	   were	   harvested	  afterwards	   to	   analyze	   the	   incorporated	   radioactivity.	   We	   observed	   a	   blunted	   [3H]-­‐DHEA-­‐FAE-­‐LDL	   uptake	   when	   excess	   cold	   LDL	   was	   presented,	   since	   a	   significant	  radioactivity	   reduction	   was	   shown	   in	   cells	   with	   unlabeled	   LDL	   incubation	   compared	  with	   the	  cells	  without	  unlabeled	  LDL	   incubation	   (I,	  Figure	  2A).	  This	   indicated	   that	   the	  DHEA-­‐FAE-­‐LDL	  uptake	  was	  mediated	  by	  LDLr	  or	  LDLr-­‐related	  proteins.	  	  
1.2	  Cell	  metabolites	  of	  DHEA-­‐FAE-­‐LDL	  	  To	  understand	   the	  metabolic	   fate	  of	   the	   internalized	  DHEA-­‐FAE-­‐LDL,	  we	  analyzed	   the	  [3H]-­‐DHEA	   and	   [3H]-­‐DHEA-­‐FAE	   contents	   in	   both	   cells	   and	   medium.	   The	   cells	   were	  incubated	  with	  [3H]-­‐DHEA-­‐FAE-­‐LDL	  for	  6	  h	  and	  chased	  for	  48	  h,	  after	  which	  the	   lipids	  were	   extracted	   from	   the	   cells	   and	   medium.	   The	   lipids	   were	   then	   resolved	   using	   a	  Sephadex	   LH-­‐20	   column	   and	   the	   solvent	   fractions	   were	   collected	   for	   analysis.	   In	   the	  fractions	  comigrating	  with	  DHEA-­‐linoleate	  standard,	  we	  detected	  [3H]	  labels	  only	  in	  the	  cell	  fractions	  but	  not	  in	  the	  medium	  fractions,	  indicating	  that	  [3H]-­‐DHEA-­‐FAE	  was	  taken	  up	  by	  the	  cells.	  We	  next	  found	  that	  most	  of	  the	  [3H]	  label	  in	  the	  medium	  corresponded	  to	  the	   standards	   of	   free	   DHEA	   and	   other	  metabolites	   (I,	   Figure	   2B).	   This	   suggested	   that	  part	   of	   the	   incorporated	   [3H]-­‐DHEA-­‐FAE	   had	   been	   hydrolyzed,	   metabolized,	   and	  effectively	  secreted	  into	  medium.	  	  We	  then	  used	  TLC	  to	   identify	  the	  metabolites.	  We	  resolved	  lipids	  that	  were	  previously	  extracted	  from	  cells	  and	  medium	  as	  (I,	  Figure	  2B)	  by	  one-­‐dimensional	  TLC,	  and	  detected	  the	  lipids	  with	  a	  cyclone	  storage	  phosphor	  system.	  The	  cellular	  radioactivity	  comigrated	  with	  the	  [3H]-­‐DHEA-­‐linoleate	  standard,	  while	  medium	  radioactivity	  partially	  comigrated	  with	   the	   [3H]-­‐DHEA	   standard	   and	   partially	   migrated	   more	   rapidly	   (I,	   Figure	   3),	   in	  agreement	  with	  the	  results	  from	  fractionation	  analysis.	  	  To	  further	  identify	  the	  unknown	  metabolites	  that	  had	  appeared	  in	  the	  medium,	  we	  used	  two-­‐dimensional	  TLC	  and	  several	  DHEA	  metabolite	  standards:	  4-­‐adione,	  5α-­‐adione,	  5α-­‐androstan-­‐3α-­‐ol-­‐17-­‐one,	   3β,5α-­‐adiol-­‐17α,	   5α-­‐dihydrotestosterone	   (5α-­‐DHT),	   3α,5α-­‐adiol,	   3β,5α-­‐adiol,	   testosterone,	   and	   5α-­‐androstan-­‐3β-­‐ol-­‐17-­‐one	   as	   reference	   steroids.	  The	   5α-­‐adione	   (mostly),	   DHEA,	   DHEA-­‐FAE,	   and	   4-­‐adione	   were	   the	   only	   steroids	  presenting	   in	   the	  medium	   (I,	   Figure	  4),	   although	   the	  possibility	   that	   small	   amounts	  of	  other	  DHEA	  metabolites	  were	  not	  detectable	  using	  this	  method	  or	  degraded	  during	  the	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chase	  time	  could	  not	  be	  excluded.	  Moreover,	  since	  steroidogenic	  enzyme	  profiles	  may	  be	  cell	   type-­‐specific,	   different	   metabolites	   and	   contents	   would	   be	   expected	   in	   other	   cell	  types	  after	  DHEA-­‐FAE	  uptake.	  	  
1.3	  Lysosomal	  acid	  lipase	  in	  DHEA-­‐FAE	  hydrolysis	  	  To	  determine	  how	  DHEA-­‐FAE-­‐LDL	  is	  metabolized	  in	  cells,	  we	  studied	  the	  role	  of	  LAL	  in	  this	  process,	  since	  it	  is	  the	  enzyme	  that	  is	  responsible	  for	  the	  hydrolysis	  of	  cholesteryl-­‐FAE-­‐LDL.	   We	   transiently	   depleted	   LAL	   by	   siRNAs	   in	   HeLa	   cells	   (I,	   Figure	   5A)	   and	  analyzed	   the	   [3H]-­‐cholesteryl-­‐FAE-­‐LDL	  hydrolysis.	  As	   expected,	   the	  hydrolysis	   of	   [3H]-­‐cholesteryl-­‐FAE-­‐LDL	   was	   significantly	   inhibited	   in	   LAL-­‐depleted	   cells	   compared	   with	  the	  control	  cells	  (I,	  Figure	  5B).	  When	  the	  [3H]-­‐DHEA-­‐FAE-­‐LDL	  was	  analyzed	  in	  the	  same	  setup,	  we	  found	  a	  different	  pattern	  from	  what	  was	  observed	  in	  the	  [3H]-­‐cholesteryl-­‐FAE-­‐LDL	   (I,	   Figure	   5B).	   First,	   there	   was	   significantly	   more	   [3H]-­‐DHEA-­‐FAE	   than	   [3H]-­‐cholesteryl-­‐FAE	   remaining	   in	   the	   control	   cells,	   indicating	   different	   kinetics	   for	   the	  hydrolysis	   of	   the	   two	   FAEs.	   Second,	   LAL	   depletion	   had	   a	   more	   modest	   effect	   on	  hydrolyzing	  the	  [3H]-­‐DHEA-­‐FAE	  than	  the	  [3H]-­‐cholesteryl-­‐FAE,	  suggesting	  that	  LAL	  was	  not	  the	  only	  enzyme	  participating	  in	  the	  hydrolysis	  of	  [3H]-­‐DHEA-­‐FAE.	  	  We	  also	  used	  Wolman	  cells	   to	   investigate	   the	   contribution	  of	  LAL	   in	   the	  hydrolysis	  of	  [3H]-­‐DHEA-­‐FAE	   and	   [3H]-­‐cholesteryl-­‐FAE.	   The	   [3H]-­‐cholesteryl-­‐FAE	   hydrolysis	   was	  abolished	  in	  these	  cells,	  as	  expected,	  since	  CE	  hydrolysis	  is	  LAL-­‐dependent;	  however,	  a	  significant	  level	  of	  [3H]-­‐DHEA-­‐FAE	  hydrolysis	  was	  still	  observed	  despite	  the	  absence	  of	  LAL	   activity	   in	   the	  Wolman	   cells.	  However,	   the	   hydrolysis	   of	   [3H]-­‐DHEA-­‐FAE	  was	   less	  efficient	  in	  the	  Wolman	  cells	  than	  in	  the	  control	  fibroblasts,	  implying	  that	  LAL	  played	  a	  partial	  role	  in	  this	  process	  (I,	  Figure	  6B).	  	  	  Together,	   this	   study	   characterized	   the	  metabolic	   processing	   of	   DHEA-­‐FAE-­‐LDL	   in	   the	  aspects	  of	  uptake,	  hydrolysis,	  and	  metabolite	  secretion	  (Figure	  6).	  By	  cellular	  hydrolysis,	  the	   inert	  DHEA-­‐FAE	   converts	   to	   biologically	   active	  DHEA	   and	   further	   to	   other	   steroid	  metabolites.	   We	   showed	   that	   LAL	   is	   not	   the	   only	   enzyme	   for	   DHEA-­‐FAE	   hydrolysis,	  suggesting	   the	   existence	   of	   other	   lipases,	   such	   as	   the	   hormone-­‐sensitive	   lipase	   that	  mediates	   E2-­‐FAE	   hydrolysis,	   which	   may	   constitute	   the	   major	   activity	   in	   DHEA-­‐FAE	  hydrolysis.	  	  	  
Figure	   6.	   Schematic	   illustration	   of	   DHEA-­FAE-­LDL	   and	   cholesteryl-­FAE-­LDL	   uptake	   and	  
hydrolysis	  in	  the	  lysosomes.	  The	  endocytic	  membrane	  trafficking	  routes	  of	  the	  LDLs	  and	  the	  
exocytic	  pathway	  of	  the	  hydrolytic	  products	  and	  metabolites	  have	  been	  simplified.	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2.	  Desmosterol	  in	  the	  developing	  brain	  	  
	  
2.1	  Desmosterol	  accumulation	  during	  brain	  development	  	  
	  In	  the	  developing	  mouse	  brain,	  desmosterol	  begins	  accumulating	  during	  embryonic	  day	  14	  until	  postnatal	  day	  10	  and	  peaks	  in	  the	  first	  postnatal	  week	  (II,	  Figure	  1B).	  Compared	  with	   desmosterol,	   other	   sterols	   do	  not	   show	   similar	   substantial	   accumulations	   during	  this	  period	  (II,	  Figure	  1C),	  and	  the	  total	  sterol	  content	  rises	  remarkably	  (II,	  Figure	  1D).	  Since	   this	   time	   window	   corresponds	   with	   the	   period	   in	   which	   neuron	   growth	   and	  synapse	   formation	   actively	   commence,	   desmosterol	   may	   play	   a	   special	   role	   in	   brain	  development.	  	  
2.2	   Accumulation	   of	   desmosterol	   during	   brain	   development	   is	   not	   caused	   by	  
transcriptional	  repression	  of	  DHCR24	  	  To	   investigate	   the	   mechanism	   that	   regulates	   desmosterol	   accumulation	   during	   brain	  development,	  we	  analyzed	  the	  transcriptional	  regulation	  of	  three	  important	  enzymes	  in	  the	   cholesterol	   biosynthesis	   pathway:	   DHCR24,	   which	   converts	   desmosterol	   to	  cholesterol;	  SQLE,	  a	  rate	  limiting	  enzyme	  in	  prelanosterol	  synthesis;	  and	  DHCR7,	  which	  removes	   the	   double	   bond	   from	   7-­‐DHC,	   an	   immediate	   precursor	   of	   cholesterol.	   We	  expected	  to	  see	  a	  decrease	  in	  the	  mRNA	  level	  of	  DHCR24	  if	  it	  accounted	  for	  desmosterol	  accumulation	  in	  the	  developing	  brain.	  However,	  reverse	  transcription-­‐polymerase	  chain	  reaction	   (RT-­‐PCR)	   showed	   that	   the	  DHCR24	   mRNA	   level	   remained	   flat	   at	   the	   highest	  level	  until	  P3,	  overlapping	  with	  desmosterol	  accumulation	  (II,	  Figure	  2).	  From	  P3	  to	  P12,	  the	  DHCR24	  mRNA	  level	  decreased,	  while	  the	  desmosterol	   level	  also	  fell.	  This	  suggests	  that	   transcriptional	   regulation	   of	   DHCR24	   is	   not	   the	   reason	   for	   desmosterol	  accumulation	  in	  the	  developing	  brain.	  Moreover,	  changes	  in	  the	  DHCR24	  mRNA	  profile	  were	  very	  similar	  to	  those	  in	  SQLE	  and	  DHCR7	  (II,	  Figure	  2),	  suggesting	  that	  DHCR24	  is	  not	   regulated	   differentially	   from	   other	   cholesterol	   synthesis	   enzymes.	   Therefore,	  instead	  of	  repressing	  the	  DHCR24	  level	  to	  cause	  desmosterol	  accumulation	  during	  brain	  development,	   it	   is	  more	   likely	   that	   desmosterol	   plays	   a	   role	   in	   feedback	   regulation	   of	  DHCR24	  expression.	  	  	  
2.3	   Accumulation	   of	   desmosterol	   during	   brain	   development	   may	   be	   caused	   by	  
posttranscriptional	  repression	  of	  DHCR24	  by	  progesterone	  
	  We	   next	   investigated	   whether	   the	   posttranslational	   regulation	   of	   DHCR24	   activity	  affected	   the	  desmosterol	  accumulation.	  Progesterone	  and	  pregnenolone	  are	  present	   in	  the	  developing	  brain	  (Ibanez	  et	  al.,	  2003).	  Moreover,	  they	  suppress	  Δ24	  reduction	  and	  induce	  desmosterol	   accumulation	   in	  vitro	   (Lindenthal	   et	   al.,	   2001;	  Panini	   et	   al.,	   1987).	  Therefore,	  we	  analyzed	  whether	  progesterone	  would	  inhibit	  DHCR24	  activity	  via	  post-­‐translational	  regulation.	  	  In	   this	   study,	   we	   used	   a	   Chinese	   hamster	   ovary	   (CHO)	   cell	   line	   stably	   expressing	  DHCR24.	   Progesterone	   incubation	  did	   not	   increase	   the	  DHCR24	  protein	   level	   in	   these	  cells	  or	   in	  control	  CHO	  cells	  (II,	  Figure	  3).	  By	  pulse-­‐labeling	  the	  control	  CHO	  cells	  with	  [14C]-­‐acetate	   in	   the	   presence	   of	   progesterone	   and	   analyzing	   the	   subsequent	   sterol	  metabolic	  products	   in	   the	   cell,	  we	   found	   that	  progesterone	  caused	  an	  accumulation	  of	  [14C]-­‐desmosterol	   and	   a	   decrease	   in	   [14C]-­‐cholesterol.	   In	   CHO	   cells	   stably	   expressing	  DHCR24,	   however,	   we	   observed	   that	   the	   [14C]-­‐desmosterol	   accumulation	   during	  progesterone	   treatment	  was	  attenuated,	   compared	  with	   that	   in	   control	  CHO	  cells,	   and	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only	   achieved	   a	   similar	   degree	   of	   [14C]-­‐desmosterol	   accumulation	   at	   higher	  progesterone	   concentrations	   (II,	   Figure	   3).	   These	   results	   indicated	   that	   progesterone	  induces	   desmosterol	   accumulation	   via	   DHCR24;	   however,	   this	   induction	   is	   not	   by	  reducing	   the	   DHCR24	   protein	   level,	   but	   most	   probably	   by	   posttranscriptionally	  inhibiting	  DHCR24	  enzymatic	  activity.	  	  
2.4	  Accumulating	  desmosterol	  may	  stimulate	  LXR	  signaling	  in	  the	  developing	  brain	  	  LXR	  mediates	  sterol	  secretion	  that	  is	  essential	  in	  the	  developing	  brain.	  Oxysterols	  were	  previously	  believed	  to	  be	  the	  only	  LXR	  regulators;	  recently,	  desmosterol	  was	  identified	  as	   another	   LXR	   stimulator	   in	   vitro	   (Yang	   et	   al.,	   2006).	   We	   tested	   the	   possibility	   that	  accumulation	  of	  desmosterol	  may	  regulate	  LXR	  target	  genes	  in	  the	  developing	  brain.	  	  	  We	   treated	   U251MG	   human	   glioma	   cells	   with	   a	   DHCR24	   inhibitor	   20,25-­‐diazacholesterol	   (DAC)	   and	   cultured	   the	   cells	   in	   LPDS	  medium	   to	   prevent	   exogenous	  cholesterol	  uptake.	   In	  2	  days,	  desmosterol	   accumulated	   to	  40%	  of	   the	   total	   sterol.	  We	  analyzed	   the	   protein	   level	   of	   the	   LXR	   target	   gene	   ABCA1	   in	   these	   cells	   by	   Western	  blotting	   and	   found	   that	   ABCA1	   level	   was	   significantly	   increased	   during	   DHCR24	  inhibition,	  suggesting	  that	  LXR	  signaling	  was	  activated	  by	  desmosterol	  (II,	  Figure	  S1A).	  	  Since	  LXR	  regulates	  genes	  that	  are	  involved	  in	  sterol	  secretion,	  we	  next	  studied	  whether	  desmosterol	  accumulation	  would	  promote	  sterol	  efflux.	  We	  analyzed	  the	  cellular	  sterols	  in	  control	  vs.	  DAC-­‐treated	  U251MG	  cells	  and	  sterols	  that	  were	  secreted	  in	  the	  medium.	  We	  observed	  an	  increase	  in	  sterols	  in	  the	  medium	  of	  DAC-­‐treated	  cells	  (II,	  Figure	  S1B).	  These	   results	   together	   suggested	   that	   desmosterol	   accumulation	   stimulates	   LXR	  signaling	  and	  subsequently	  enhances	   sterol	   secretion	   in	  astrocytic	   cells.	  This	   is	   in	   line	  with	   the	   result	   from	   a	   previous	   study	   that	   desmosterol-­‐loaded	   primary	   astrocytes	  exhibited	   a	  marked	   increase	   in	   both	   protein	   and	  mRNA	   levels	   of	   ABCA1	   (Wang	   et	   al.,	  2008).	  	  	  
2.5	  Accumulating	  desmosterol	  may	  prevent	  sterol	  esterification	  and	  24-­‐OHC	  formation	  in	  
the	  developing	  brain	  	  In	   analyzing	   the	   sterol	   profile	   during	   desmosterol	   accumulation	   induced	   by	   DAC,	   we	  also	   observed	   a	   decrease	   in	   sterol	   ester	   levels	   in	   DAC-­‐treated	   cells	   (II,	   Figure	   1B),	  indicating	   that	   desmosterol	   accumulation	   inhibits	   sterol	   esterification.	   This	   was	  evidenced	   as	   the	   desmosterol	   accumulation	   in	   the	   developing	   mouse	   brain,	   which	  coincided	  with	  decreased	  sterol	  ester	  levels	  (II,	  Figure	  1D).	  By	  maintaining	  sterols	  in	  the	  active	   and	   functional	   unesterified	   form,	   desmosterol	   could	   be	   important	   for	   brain	  activities	  in	  the	  developing	  brain.	  	  	  On	  the	  other	  hand,	  desmosterol	  accumulation	  could	  be	  beneficial	  by	  preventing	  24-­‐OHC	  formation	   and	   subsequent	   sterol	   egression	   from	   the	   CNS	   during	   brain	   development.	  	  Since	   desmosterol	   cannot	   be	   hydrolyzed	   as	   cholesterol	   at	   C24	   to	   generate	   24-­‐OHC,	  which	  passes	  through	  the	  BBB	  (Ohyama	  et	  al.,	  2006),	  the	  brain	  could	  effectively	  utilize	  
de	   novo-­	   synthesized	   sterols	   by	   accumulating	   sterols	   as	   desmosterol	   instead	   of	  cholesterol.	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3.	  APP	  and	  proteolysis	  products	  in	  cholesterol	  synthesis	  regulation	  	  	  Several	   studies	   have	   pointed	   to	   the	   connection	   between	   APP	   and	   cholesterol	  homeostasis,	   especially	   in	   attempts	   to	   understand	   the	   role	   of	   cholesterol	   in	   AD	  pathogenesis	  using	  AD	  mouse	  models.	  In	  this	  study,	  we	  aimed	  to	  address	  the	  ubiquitous	  physiological	  role	  of	  APP	  and	  its	  proteolytic	  fragments	  in	  regulating	  cholesterol	  balance,	  using	   human	   astrocytic	   (U251MG),	   hepatic	   (HepG2),	   and	   fibroblastic	   cells.	   Astrocytes	  are	  considered	  to	  be	  important	  cholesterol-­‐producing	  cells	  in	  the	  CNS,	  hepatocytes	  are	  key	   cholesterol-­‐synthesizing	   cells	   at	   the	   whole-­‐body	   level,	   and	   fibroblasts	   are	   major	  cholesterol-­‐receiving	  cells	  via	  LDL	  uptake.	  	  	  
3.1	  Role	  of	  APP	  in	  cholesterol	  regulation	  	  First,	  we	  studied	  cholesterol	  synthesis	   in	  cells	  with	  transient	  APP	  depletion.	  APP	  has	  a	  short	   half-­‐life	  measured	   in	   hours.	   In	   U251MG	   astrocytoma	   cells	   transfected	  with	   APP	  siRNA	  oligos	   for	  6	  h,	   12	  h	   and	  24	  h,	  we	  observed	  APP	  depletion	  by	  ~50%	   in	  6	  h	   and	  ~90%	  in	  24	  h	  (III,	  Figure	  1A).	  APLP2	  depletion	  in	  U251MG	  cells	  could	  also	  be	  achieved	  in	   24	   h	   by	   siRNA	   oligo	   transfection	   (III,	   Figure	   S4A).	   Interestingly,	   APP	   and	   APLP2	  compensated	  mutually	   in	   their	   protein	   levels	  when	  one	  was	  depleted	   for	   a	   prolonged	  time,	   i.e.	   3	   days	   (III,	   Figure	   S4D).	   This	   implies	   that	   the	   two	   APP	   family	   proteins	  may	  serve	   similar	   functions,	  which	   is	   in	   agreement	  with	   (Shariati	   and	  De	   Strooper,	   2013).	  Therefore,	   the	   transient	   approach	   is	  more	   suitable	   for	   studying	   the	  direct	   role	   of	  APP	  family	  proteins	  than	  using	  mouse	  models	  that	  have	  been	  heavily	  used	  in	  AD	  research.	  	  In	  cells	  with	  APP	  depletion	  for	  24	  h	  or	   less,	   the	  cholesterol	   level	  was	  reduced	  by	  10%,	  independent	   of	   serum	   conditions	   (III,	   Figure	   1B).	   In	   cells	   cultured	   under	   serum-­‐deprived	   conditions	   in	  which	   cellular	   cholesterol	   level	   relies	   on	  de	  novo	   synthesis,	  we	  observed	   that	   [3H]-­‐cholesterol	   synthesized	   from	   [3H]-­‐acetate	   was	   also	   substantially	  decreased	   (III,	   Figure	  1C).	  The	   same	  downregulation	   in	   cholesterol	   synthesis	  was	  also	  observed	  in	  APLP2-­‐depleted	  cells	  (III,	  Figure	  S4B).	  	  	  To	   prove	   that	   APP	   depletion-­‐induced	   down-­‐regulation	   in	   cholesterol	   synthesis	   is	  specific,	   we	   introduced	  wild-­‐type	   APP	   (695)	   to	   APP-­‐depleted	   U251MG	   cells.	   Bringing	  back	  APP	  to	  the	  cells	  resulted	  in	  a	  recovery	  in	  cholesterol	  de	  novo	  synthesis,	  confirming	  the	  direct	  role	  of	  APP	  in	  cholesterol	  regulation	  (III,	  Figure	  1E).	  	  	  	  Interestingly,	  a	  recent	  study	  showed	  that	  APP	  directly	  interacts	  at	  its	  GXXXG	  motif	  with	  SREBP1	  in	  the	  Golgi,	  prohibiting	  the	  S2P	  processing	  of	  SREBP1	  and	  consequent	  HMGR	  expression	   and	   cholesterol	   synthesis	   in	   neurons,	   but	   not	   in	   astrocytes	   (Pierrot	   et	   al.,	  2013).	   Since	   SREBP2,	   instead	   of	   SREBP1,	   is	   the	   major	   regulator	   of	   cholesterol	  metabolism	  (Horton	  et	  al.,	  2002),	  it	  would	  be	  interesting	  to	  examine	  whether	  APP	  is	  able	  to	  bind	  SREBP2	  and	  affect	  cholesterol	  synthesis	  as	  well.	  Because	  the	  GXXXG	  motif	  is	  also	  the	  binding	  site	  of	  APP	  with	  cholesterol	  (Barrett	  et	  al.,	  2012),	  cholesterol	  may	  facilitate	  the	   APP-­‐SREBP	   interaction,	   resulting	   in	   reduced	   SREBP	   processing	   and	   consequently	  decreased	   cholesterol	   synthesis	   in	   conditions	  with	  abundant	   cholesterol.	   Future	   study	  would	  be	  beneficial	  to	  test	  this	  hypothesis.	  	  
3.2	  APP	  fragments	  in	  regulating	  cholesterol	  synthesis	  	  APP	  undergoes	  a	  complicated	  processing	  in	  cells	  (III,	  Figure	  1D);	  thus,	  our	  observation	  of	   the	   regulatory	   role	   for	   APP	   in	   regulating	   cholesterol	   synthesis	   needed	   to	   be	  
	  	  	  
	  
36	  
elucidated	   further	   in	   terms	   of	   APP-­‐processing	   products.	  We	  dissected	   the	   role	   of	   APP	  fragments,	  using	  the	  cholesterol	  synthesis	  rescue	  assay	  as	  readout.	  	  	  We	   obtained	   the	   point-­‐mutant	   APP	   construct	   APP-­‐M596V,	   which	   is	   deficient	   in	   β-­‐processing	  and,	  therefore,	  generates	  C83	  and	  APPsα	  only	  (III,	  Figure	  1F).	  We	  generated	  another	   point-­‐mutant	   APP	   construct,	   APP-­‐F615P,	   which	   predominantly	   undergoes	   β-­‐cleavage	   and	   consequently	   produces	   C99	   and	   APPsβ (III,	   Figure	   1F).	   In	   APP-­‐depleted	  U251MG	  cells,	  overexpression	  of	  APP-­‐M596V	  rescued	  cholesterol	  synthesis	  to	  the	  same	  level	  as	  did	  wild-­‐type	  APP,	  while	  APP-­‐F615P	  only	  rescued	  to	  a	  lesser	  extent	  (III,	  Figure	  1E).	   Interestingly,	   overexpression	   of	   an	   ER-­‐retention	   APP	   construct,	   APP-­‐KKAA,	  significantly	   inhibited	   cholesterol	   synthesis	   (III,	   Figure	   1E).	   Due	   to	   the	   dilysine	   ER	  retrieval	  mutation	  in	  the	  APP	  C-­‐terminal,	  APP-­‐KKAA	  does	  not	  reach	  the	  trans-­‐Golgi/PM	  where	  most	  α-­‐cleavage	   occurs	   (Skovronsky	   et	   al.,	   1998).	   This	   suggests	   that	   products	  from	   both	  α-­‐	   vs.	  β-­‐cleavage,	   i.e.	   C83	   and	   APPsα	   vs.	   C99	   and	   APPsβ,	   contribute	   to	   the	  differentially	  regulated	  cholesterol	  synthesis.	  	  	  Since	   Aβ40	   has	   been	   shown	   to	   inhibit	   cholesterol	   synthesis	   (Grimm	   et	   al.,	   2005),	   we	  measured	  Aβ	  levels	  in	  the	  media	  from	  the	  conditions	  above.	  ELISA	  analysis	  of	  Aβ40	  and	  Aβ42	   levels	   in	   the	   conditioned	  media	   did	   not	   show	  a	   corresponding	  pattern	   as	   in	   the	  cholesterol	  synthesis	  assay	  (III,	  Figure	  S1A),	  suggesting	  that	  both	  Aβ40 and	  Αβ42	  did	  not	  account	  for	  the	  differential	  regulations	  by	  APP-­‐M596V	  and	  APP-­‐F615P.	  	  We	  next	   tested	  APP	  C-­‐terminal	   intracellular	   fragments	   in	   cholesterol	   synthesis	   rescue	  assay.	   All	   C83,	   C99	   and	   C59	   (AICD)	   restored	   the	   synthesis	   in	   APP-­‐depleted	   cells	   (III,	  Figure	  1G).	  Because	  C99	  can	  be	  a	  substrate	  for α-­‐secretase	  to	  generate	  C83	  (Jager	  et	  al.,	  2009),	  we	  generated	  a	  C99-­‐F615P	  mutant	  construct	  that	  escapes	  from	  α-­‐cleavage.	  C99-­‐F615P	  overexpression	  showed	  no	  difference	  from	  other	  APP	  C-­‐terminal	  fragments	  (III;	  Figure	  1G).	  This	  indicates	  that	  all	  APP	  C-­‐terminal	  fragments,	  no	  matter	  whether	  they	  are	  processed	  by	  α-­‐	  or	  β-­‐secretase,	  are	  capable	  of	  rescuing	  cholesterol	  synthesis.	  Therefore,	  the	   shared	   proteolytic	   end	   product	   C59/AICD	   in	   C83	   and	   C99	   may	   account	   for	   this	  activity.	  	  
3.3	  APP	  regulates	  cholesterol	  synthesis	  via	  the	  SREBP2	  pathway	  	  We	   next	   investigated	   the	   mechanism	   of	   APP-­‐mediated	   cholesterol	   regulation	   by	  examining	   three	   cholesterol-­‐specific	   genes:	  HMGR,	  CYP51	   and	  LDLr.	  HMGR	  and	  CYP51	  are	  rate-­‐limiting	  enzymes	  in	  the	  cholesterol	  synthesis	  pathway,	  and	  LDLr	  is	  responsible	  for	   cellular	   uptake	   of	   exogenous	   cholesterol.	   Due	   to	   the	   importance	   of	  HMGR,	   CYP51,	  and	  LDLr	  in	  cholesterol	  balance,	  we	  analyzed	  their	  mRNA	  and	  protein	  levels	  in	  U251MG	  cells	  with	  24-­‐h	  APP	  depletion.	  The	  transcript	  levels	  all	  plunged	  (III,	  Figure	  2A)	  and	  the	  protein	  levels	  were	  also	  reduced	  accordingly	  (III,	  Figure	  2B).	  Since	  these	  three	  genes	  are	  transcriptionally	  regulated	  by	  SREBP2	  at	  their	  SRE,	  we	  analyzed	  the	  SRE	  activity,	  using	  an	   LDLr	   promoter-­‐driven	   luciferase	   reporter	   construct.	   We	   found	   decreased	   SRE	  activity	  in	  APP-­‐depleted	  cells	  (III,	  Figure	  2C);	  similar	  reduction	  was	  also	  seen	  in	  APLP2-­‐depleted	  cells	  (III,	  Figure	  S4C).	  This	  was	  due	  to	  downregulation	  of	  SREBP2	  activity,	  since	  we	  observed	  a	  decrease	  in	  mature	  SREBP2	  protein	  level	  in	  the	  nuclear	  fraction	  of	  APP-­‐depleted	  cells	  (III,	  Figure	  2D).	  In	  addition,	  the	  SREBP2	  precursor	  level	  was	  also	  reduced	  (III,	  Figure	  2D).	  	  Experimental	   results	   in	  NPC1-­‐depleted	  U251MG	   cells	   further	   argued	   for	   an	   inhibitory	  role	   of	   the	  APP	  β-­‐processing	   products	   in	   regulating	   cholesterol	   synthesis	   via	   SREBP2.	  NPC1	  depletion	  in	  U251MG	  cells	  showed	  increased	  cholesterol	  synthesis	  (III,	  Figure	  2E),	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as	   expected	   due	   to	   an	   endo-­‐lysosomal	   cholesterol	   accumulation	   and	   ER	   cholesterol	  depletion,	   thereby	   an	   activated	   SREBP2	   signaling,	   in	   this	   condition	   (Ikonen,	   2006).	   In	  the	   meanwhile,	   APP	   β-­‐cleavage	   was	   enhanced	   in	   NPC1-­‐depleted	   cells,	   as	   seen	   in	  decreased	   APPsα	   secretion	   and	   increased	   cellular	   C99	   protein	   level	   (III,	   Figure	   2F).	  Interestingly,	  no	  change	  in	  Aβ40	  and	  Aβ42	  levels	  in	  the	  medium	  was	  shown	  (III,	  Figure	  S1B).	   When	   APP	   was	   depleted	   together	   with	   NPC1,	   a	   further	   increase	   in	   cholesterol	  synthesis	  was	  observed	  (III,	  Figure	  2E),	  indicating	  APP	  β-­‐processing	  products	  imposed	  a	  negative	  regulatory	  role	  in	  SREBP2-­‐regulated	  cholesterol	  synthesis.	  	  	  	  
3.4	  APP	  ectodomains	  regulate	  cholesterol	  synthesis	  via	  the	  SREBP2	  pathway	  	  Due	   to	   the	   different	   regulatory	   effects	   of	   APP-­‐M596V	   and	   APP-­‐F615P	   on	   cholesterol	  synthesis,	  yet	  the	  same	  effect	  of	  their	  C-­‐terminal	  fragments,	  we	  hypothesized	  that	  there	  could	  be	  a	  distinct	  biological	  function	  in	  APP	  N-­‐terminal	  fragments,	  i.e.	  secreted	  APPsα	  and	   APPsβ	   ectodomains.	   Both	   APPsα	   and	   APPsβ	   were	   detectable	   in	   the	   conditioned	  medium	   of	   U251MG	   cells	   that	   had	   been	   depleted	   with	   endogenous	   APP	   and	  overexpressed	  with	  APP-­‐M596V	  or	  APP-­‐F615P	  constructs,	  respectively	  (III,	  Figure	  S2A).	  We	  used	  this	  conditioned	  medium	  as	  a	  donor	  medium	  to	  feed	  the	  APP-­‐depleted	  acceptor	  cells	  (III,	  Figure	  3A).	  In	  examining	  the	  cholesterol	  synthesis	  and	  SRE	  activity	  in	  acceptor	  cells,	   APP-­‐M596V	   donor	   medium	   not	   only	   restored	   cholesterol	   synthesis,	   but	   also	  rescued	  SRE	  activity	   (III,	  Figures	  3B	  and	  3C);	  however,	   the	  APP-­‐F615P	  donor	  medium	  did	  not	  affect	  cholesterol	  synthesis	  (III,	  Figure	  3B).	  If	  APP-­‐F615P	  donor	  medium	  acts	  as	  a	   negative	   regulator,	   the	   effect	   could	   be	  masked	   because	   of	   the	   significantly	   reduced	  basal	  cholesterol	  synthesis	   in	  the	  acceptor	  cells.	  Thus,	  we	  tested	  the	  APP-­‐F615P	  donor	  medium	   on	   untreated	   U251MG	   acceptor	   cells	   (III,	   Figure	   3D)	   and	   we	   observed	  attenuation	  in	  both	  cholesterol	  synthesis	  and	  SRE	  activity	  (III,	  Figures	  3E	  and	  3F).	  	  	  To	   exclude	   the	   possibility	   that	   the	   donor	   medium	   contained	   molecules	   that	   secreted	  together	   with	   APPsα	   or	   APPsβ and	   acted	   in	   the	   signaling	   pathway	   of	   cholesterol	  synthesis,	  we	  used	  purified	  recombinant	  APPsα	  and	  APPsβ	  peptides	  to	  feed	  the	  acceptor	  cells	  as	  in	  the	  donor	  medium	  transfer	  experiments.	  We	  first	  measured	  the	  concentration	  of	  APPsα	  or	  APPsβ in	  the	  donor	  medium	  in	  previous	  experiments	  (III,	  Figure	  S2B).	  The	  5-­‐nM	   concentrations	   of	   both	   APPsα	   and	   APPsβ	   in	   the	   donor	   medium	   as	   detected	   by	  their	  specific	  antibodies	  were	  in	  the	  physiological	  range	  of	  APP	  ectodomain	  levels	  in	  the	  cerebrospinal	  fluid	  (Rosen	  et	  al.,	  2012).	  Recombinant	  APPsα	  and	  APPsβ	  peptides	  at	  this	  concentration	  were	  also	  effective	   in	  both	  cholesterol	  synthesis	  and	  SRE	  activity	  assays	  (III,	  Figure	  S2C).	  We	  next	  observed	   increased	  cholesterol	  synthesis	  and	  SRE	  activity	   in	  cholesterol-­‐low	  cells	  cultured	  with	  APPsα	  peptide,	  but	  not	  with	  APPsβ	  (III,	  Figures	  S3A	  and	  3G),	  and	  contrasting	  results	  in	  cholesterol-­‐normal	  cells	  cultured	  with	  APPsβ	  peptide	  (III,	  Figures	  S3B	  and	  3H).	  This	   result	   confirms	   that	   the	   two	  APP	  ectodomains	   function	  opposingly	  in	  cholesterol	  synthesis	  regulation	  via	  the	  SREBP2	  pathway.	  	  
3.5	  APP	  dose	  effect	  on	  cholesterol	  synthesis	  in	  liver	  cells	  	  	  To	   further	  study	   the	  regulatory	  role	  of	  APP	   in	  SREBP2	  signaling	   in	  cells	   specialized	   in	  sterol	   metabolism,	   we	   used	   a	   human	   hepatoblastoma	   cell	   line,	   HepG2,	   which	   is	   a	  commonly	  used	  cell	  model	  in	  lipid	  research.	  We	  started	  with	  depleting	  endogenous	  APP	  protein	   in	   HepG2	   cells;	   however	   the	   knocking-­‐down	   efficiency	   was	   not	   as	   high	   as	   in	  U251MG	   cells,	   partially	   because	   the	   endogenous	  APP	   level	  was	   higher	   in	  HepG2	   cells.	  Therefore,	   we	   continued	   with	   overexpressing	   the	   wild-­‐type	   APP	   in	   HepG2	   cells	   by	  transient	  transfection	  and	  measured	  the	  subsequent	  cholesterol	  synthesis	  and	  LDLr	  SRE	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activity	   by	   luciferase	   reporter	   assay.	   	  We	   observed	   enhanced	   cholesterol	   synthesis	   in	  APP-­‐overexpressing	  HepG2	  cells	  (III,	  Figure	  S3C).	  Increasing	  the	  APP	  protein	  level	  also	  doubled	  the	  LDLr	  SRE	  activity	  in	  the	  HepG2	  cells,	  which	  indicates	  that	  APP	  has	  a	  dosage	  effect	   (III,	   Figure	   4A).	   We	   then	   overexpressed	   APP-­‐M596V	   or	   APP-­‐F615P	   mutant	  constructs	   in	   the	   HepG2	   cells	   to	   compare	   with	   the	   effects	   brought	   by	   wild-­‐type	   APP	  overexpression.	   In	   accordance	   with	   our	   previous	   findings,	   overexpressing	   the	   APP-­‐M596V	   increased	   the	   SRE	   luciferase	   activity.	   On	   the	   other	   hand,	   overexpressing	   the	  APP-­‐F615P	   also	   led	   to	   an	   increase	   in	   SRE	   activity,	   but	   to	   a	   significantly	   lower	   extent	  compared	   with	   that	   of	   expressing	   wild-­‐type	   APP	   or	   APP-­‐M596V	   (III,	   Figure	   4A),	  probably	  due	  to	  a	  high	  basal	  APP	  level.	  	  It	  suggests	  that,	  despite	  a	  dosage	  effect	  of	  APP,	  the	  difference	  between	  wild-­‐type	  APP/APP-­‐M596V	  as	  efficient	  positive	   regulators	  and	  APP-­‐F615P	   as	   a	   less	   efficient	   regulator	   is	   significant.	   These	   results	  were	   confirmed	   in	  U251MG	  cells	  overexpressing	  these	  constructs	  (III,	  Figure	  4A).	  	  To	  characterize	  this	  regulation	  in	  HepG2	  cells,	  we	  measured	  the	  LDLr	  protein	  level	  (III,	  Figure	  4B)	  and	  Dil-­‐LDL	  uptake	  (III,	  Figure	  4C)	  in	  cells	  overexpressing	  either	  wild-­‐type	  or	  mutant	  APP	  constructs.	  Not	  surprisingly,	   the	  LDLr	  protein	   level	  was	   increased	  and	  the	  Dil-­‐LDL	   uptake	   was	   enhanced	   significantly	   in	   wild-­‐type	   APP	   or	   APP-­‐M596V-­‐overexpressing	   cells,	   while	   the	   LDLr	   level	   was	   slightly	   but	   significantly	   decreased	   in	  APP-­‐F615P-­‐overexpressing	  cells.	  	  	  	  We	   next	   fed	   HepG2	   cells	   with	   donor	  medium	   from	   cells	   overexpressing	   wild-­‐type	   or	  mutant	   APP	   constructs	   and	   examined	   the	   LDLr	   SRE	   activity,	   to	   test	   the	   role	   of	   APP	  ectodomains	  in	  cholesterol	  synthesis	  in	  HepG2	  cells.	  In	  line	  with	  results	  from	  the	  LDLr	  uptake	   assay,	  wild-­‐type	  APP	  or	  APP-­‐M596V	  overexpression	   resulted	   in	   an	   increase	   in	  SRE	  activity,	  but	  APP-­‐F615P	  overexpression	  did	  not	  (III,	  Figure	  4D).	  Same	  observation	  was	   made	   using	   the	   recombinant	   APPsα	   and	   APPsβ	   peptides	   (III,	   Figure	   4E).	   In	   an	  attempt	   to	   understand	   the	   underlying	   mechanism	   for	   the	   APPsα-­‐regulating	   SRE	  pathway,	  we	  analyzed	  GSK3β	  phosphorylation	  in	  acceptor	  cells.	  GSK3β	   is	  an	  important	  signaling	   molecule	   that	   receives	   signals	   converging	   via	   several	   pathways.	   The	  constitutively	  active	  GSK3β	  promotes	  proteasome	  degradation	  of	  mature	  SREBP2,	  and	  phosphorylation	   of	   GSK3β	   at	   S9	   inhibits	   GSK3β	   activity	   (Du	   et	   al.,	   2006;	   Ying	   et	   al.,	  2012),	   thus	   enabling	   SREBP2	   to	   be	   active	   in	   target	   gene	   transcription.	   By	  immunoblotting	   using	   a	   phospho-­‐specific	   antibody,	   we	   found	   an	   increase	   in	   GSK3β	  phosphorylation	  at	  S9	  in	  acceptor	  HepG2	  cells	  treated	  with	  APP-­‐M596V	  donor	  medium	  for	  1	  h	  (Figure	  7).	  This	  points	  out	  a	  signaling	  response	  in	  cells	  upon	  APPsα	  ectodomain	  stimulation,	  rendering	  a	  rapid	  response	  in	  cholesterol	  balance	  regulation.	  Future	  study	  of	  the	  signaling	  pathway	  in	  further	  detail	  would	  be	  beneficial.	  	  
Figure 7. GSK3β phosphorylation at S9 in HepG2 cells upon 1 h incubation with or without 
APP-M596V donor medium (n=6). 
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3.6	  SREBP2	  targets	  in	  familial	  AD	  patients	  with	  APP	  duplication	  	  Having	  observed	  the	  dosage	  effect	  of	  APP	  on	  SREBP2	  signaling	  in	  HepG2	  cells,	  we	  then	  aimed	   at	   this	   regulatory	   change	   under	   naturally	   occurring	   conditions	   at	   high	   APP	  dosages.	  We	   obtained	   human	   primary	   fibroblasts	   from	   APPDp	   patients	   as	   a	  model	   for	  this	  study.	  	  These	   APPDp	   patients	   were	   found	   in	   four	   generations	   of	   a	   Finnish	   family,	   exhibiting	  clinical	   features,	   including	   progressive	   cognitive	   decline,	   characteristic	   of	   AD.	   The	  patients	  were	   characterized	   as	   having	   an	  APP	   locus	   duplication	   rather	   than	  APP	   gene	  point	   mutation	   (Rovelet-­‐Lecrux	   et	   al.,	   2007).	   Therefore,	   it	   suggests	   that	   APP	   has	   a	  dosage	  effect	  on	  the	  AD	  pathology	  manifested	  in	  APPDp	  patients.	  	  	  	  To	  carry	  out	  this	  study,	  we	  chose	  APPDp	  primary	  fibroblasts	  from	  two	  patients	  who	  had	  not	  been	  treated	  with	  cholesterol-­‐lowering	  statin,	  and	  two	  commercial	  human	  primary	  fibroblasts	   (GM323	   and	   AG)	   as	   controls.	   We	   first	   tested	   if	   we	   could	   reproduce	   APP	  depletion-­‐induced	   LDLr	   protein	   level	   reduction	   as	   observed	   in	   U251MG	   cells.	   About	  60%	   of	   the	   endogenous	   APP	   protein	   in	   APPDp	   fibroblasts	   was	   depleted	   by	   siRNA	  transient	  transfection,	  while	  the	  LDLr	  protein	  level	  was	  decreased	  by	  ~30%	  (III,	  Figure	  5A).	   We	   then	   compared	   the	   endogenous	   APP	   and	   LDLr	   protein	   levels	   in	   control	   and	  APPDp	   fibroblasts.	   Although	   the	   APP	   level	   in	   one	   control	   fibroblast	   cell	   line	   was	   not	  significantly	   lower	   than	   in	   both	   APPDp	   fibroblast	   cell	   lines,	   the	   LDLr	   levels	   were	  strikingly	   lower	   in	   APPDp	   fibroblasts	   than	   in	   the	   controls	   (III,	   Figure	   5B).	   Considering	  our	  previous	  findings	  that	  β-­‐processing	  of	  APP	  downregulates	  the	  SREBP2	  pathway,	  the	  lowered	   LDLr	   protein	   level	   in	   APPDp	   fibroblasts	   indicates	   that	   endogenous	   APP	   may	  experience	  enhanced	  β-­‐cleavage.	  	  	  In	   a	   recently	   published	   article	   (Ikonen,	   2008)	   examining	   the	   reprograming	   of	   APPDp	  primary	   fibroblasts	   into	   induced	   pluripotent	   stem	   cells	  (iPSCs),	   iPSC-­‐derived	   neurons	  significantly	  increased	  the	  numbers	  of	  Rab5-­‐positive	  large	  early	  endosomes	  (>1	  µm3	  in	  volume)	   relative	   to	   controls.	   Endosome	   dysfunction	   and	   enlarged	   size	   were	   found	   in	  cells	   from	   a	   Down’s	   syndrome	   patient	   with	   an	   extra	   copy	   of	   the	   APP	   gene,	   and	   this	  abnormality	   in	   endosome	   morphology	   and	   function	   could	   be	   corrected	   by	   inhibiting	  BACE1	   (Jiang	   et	   al.,	   2010).	   	   We	   observed	   a	   similar	   endosome	   phenotype	   in	   APPDp	  fibroblasts.	   By	   staining	   control	   and	   patient	   fibroblasts	   with	   anti-­‐EEA1	   antibody,	   we	  found	   that	   in	   APPDp	   fibroblasts,	   EEA1-­‐positive	   large	   early	   endosomes	   (>1	   µm2)	  comprised	  ~18%	  of	  the	  total	  endosomes,	  but	  only	  ~8%	  in	  control	  fibroblasts	  (III,	  Figure	  5C).	  This	  suggests	  β-­‐processing	  of	  APP	  may	  be	  favored	  in	  APPDp	  fibroblasts.	  To	  test	  this	  hypothesis,	   we	   treated	   APPDp	   fibroblasts	   with	   BACE1	   inhibitor	   or	   siRNA	   oligos	   and	  measured	   the	  cellular	  LDLr	  protein	   level	  by	  Western	  blotting.	  An	   increase	   in	   the	  LDLr	  level	  was	  seen	  after	  either	   treatment	  (III,	  Figure	  5D),	   indicating	   that	  APP	  β-­‐processing	  caused	   suppression	  of	   the	   LDLr	  protein	   level	   in	  APPDp	  fibroblasts,	   at	   least	   partially.	   In	  accordance	  with	  this,	  we	  observed	   increased	  Dil-­‐LDL	  uptake	   in	  BACE	  inhibitor-­‐treated	  APPDp	  fibroblasts	  (III,	  Figure	  5E).	  	  	  To	  understand	  the	  correlation	  between	  sterol	   levels	  and	  APP	  duplication,	  we	  obtained	  serum	  samples	  collected	  from	  two	  APPDp	  patients	  who	  were	  the	  donors	  of	  the	  primary	  fibroblasts.	   We	   analyzed	   the	   serum	   sterol	   levels	   by	   gas-­‐liquid	   chromatography	   (III,	  Table	  I).	  The	  cholesterol	  levels	  in	  the	  sera	  from	  these	  two	  patients	  were	  in	  the	  range	  of	  those	  from	  healthy	  individuals.	  However,	  the	  ratios	  of	  other	  minor	  circulating	  sterols	  to	  cholesterol	  are	  more	  specific	   indicators	   in	  studying	  cholesterol	  metabolism	  (Miettinen	  et	   al.,	   2011).	   To	   assess	   cholesterol	   absorption,	   plant	   sterol	   (cholestanol,	   campesterol,	  and	  sitosterol)	  to	  cholesterol	  ratios	  were	  determined	  and	  they	  were	  all	   in	  the	  range	  of	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reference	   values,	   suggesting	   that	   cholesterol	   absorption	   was	   not	   impaired	   in	   APPDp	  patients.	   For	   cholesterol	   de	   novo	   synthesis,	   squalene	   and	   cholesterol	   precursor	  (lathosterol	   and	   desmosterol)	   to	   cholesterol	   ratios	   were	   measured.	   In	   both	   APPDp	  patient	   serum	   samples,	   the	   squalene:cholesterol	   and	   lathosterol:cholesterol	   ratios	   fell	  out	   of	   the	   reference	   value	   range,	   indicating	   that	   cholesterol	   synthesis	  was	  weakened.	  Interestingly,	   the	  desmosterol:cholesterol	   ratio	  was	  normal	   in	  both	  samples.	  This	   is	   in	  line	  with	   the	  alternative	  regulation	  of	  desmosterol	  via	  LXR-­‐regulated	  DHCR24	  activity,	  apart	   from	   the	   conventional	   SREBP2-­‐mediated	   control	   over	   the	   squalene	   and	  lathosterol	  levels.	  	  	  	  Together,	   these	   results	   suggest	   that	   in	   fibroblasts	   where	   sterols	   are	   not	   actively	  synthesized,	   APP	   β-­‐processing	   also	   plays	   a	   role	   in	   regulating	   the	   LDLr	   level	   and	   LDL	  uptake,	  presumably	  via	  the	  SREBP2	  pathway.	  	  	  
3.7	  APP	  knockdown	  in	  primary	  astrocytes	  
	  Since	  ABCA1	  and	  ApoE	  are	  the	  two	  proteins	  in	  charge	  of	  cholesterol	  efflux,	  we	  aimed	  at	  determining	   their	   cellular	   levels	  upon	  APPsα	   addition.	   Since	   the	  ApoE	  protein	   level	   is	  too	  low	  to	  observe	  in	  both	  U251MG	  and	  CCF	  astrocytoma	  cell	  lines	  (unpublished	  data),	  we	  used	  primary	  astrocytes	  from	  embryonic	  mouse	  brain	  for	  this	  purpose.	  We	  did	  not	  observe	   a	   significant	   change	   in	   the	   ABCA1	   level	   in	   the	   astrocytes	   with	   20-­‐h	  APPsα incubation,	   leaving	   open	   the	   possibility	   of	   responses	   from	   other	   ABC	   family	  proteins.	   Indeed,	   a	   previous	   report	   showed	   that	   the	   cholesterol	   efflux	   from	   cerebellar	  astrocytes	  is	  different	  from	  that	  in	  peripheral	  cells,	  and	  it	  does	  not	  correlate	  with	  ABCA1	  expression	   (Karten	   et	   al.,	   2006).	  We	   likewise	   did	   not	   observe	   a	   change	   in	   the	   cellular	  ApoE	   level;	   however,	   the	   ApoE	   level	   in	   the	  medium	  was	   significantly	   increased.	   This	  means	   that	   either	   astrocytes	   generate	   more	   ApoE	   and	   secret	   them	   to	   facilitate	  cholesterol	  efflux,	  or	  more	  ApoE	  is	  stabilized	  in	  the	  medium	  (Figure	  8).	  
 
Figure 8. ApoE levels in primary astrocytes incubated with APPsα. Western blotting and 
band intensity quantification for (A) ApoE in mouse primary astrocytes and (B) conditioned 
astrocyte medium. The cells were incubated with 5 nM APPsα  for 20 h in serum-free medium 
before collecting for analysis. 	  
	  	  	  
3.8	  Proposed	  model	  for	  the	  role	  of	  APP	  in	  cholesterol	  balance	  in	  the	  CNS	  
	  Based	  on	  the	   literature	  and	  our	   findings,	  we	  proposed	  a	  model	   for	  cholesterol	  balance	  regulation	   by	   APP	   in	   the	   neuron-­‐astrocyte	   context	   (Figure	   9).	   Astrocytes,	   as	   sterol	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providers	   for	   neuronal	   cells,	   synthesize	   cholesterol	   and	   secret	   it	   via	   ApoE-­‐containing	  lipoproteins	  particles.	  Neurons,	   on	   the	   other	   hand,	   are	  more	   considered	   as	   sources	   of	  APP	   and	   the	   recipients	   of	   exogenous	   cholesterol	   generated	   by	   astrocytes.	   When	   the	  neuronal	   cholesterol	   content	   is	   low,	   APP	   undergoes	   processing	   via	   the	   non-­‐amyloidogenic	   pathway.	   APP	   is	   cleaved	   in	   the	   PM	   by	   α-­‐secretase	   and	   the	  APPsα generated	   is	   released	   from	   the	   cell.	   APPsα	   stimulates	   SREBP2	   activity	   in	   the	  surrounding	  astrocyte(s),	   presumably	  via	   a	   signaling	   cascade.	  This	  helps	   astrocytes	   to	  increase	   their	  cholesterol	   synthesis	   to	  deliver	   increasing	  amounts	  of	   sterol	   to	  neurons	  
via	  ApoE	  lipoprotein	  particles.	  Upon	  γ-­‐cleavage,	  the	  intracellularly	  released	  AICD	  in	  turn	  activates	   SREBP2-­‐dependent	   gene	   transcription,	   leading to	   increased	   neuronal	  cholesterol	   production.	   When	   the	   neuronal	   cholesterol	   content	   increases	   over	   a	  threshold	   -­‐	   with	   endosomal	   cholesterol	   serving	   as	   a	   likely	   barometer	   -­‐	   APP	   becomes	  increasingly	   processed	   via	   the	   amyloidogenic	   pathway	   within	   the	   endosomal	  compartments.	  APPsβ	  and	  Aβ,	  the	  cleavage	  products	  of	  APP	  by	  β-­‐	  and	  γ-­‐secretases,	  are	  secreted	   from	   neurons	   and	   suppress	   SREBP2-­‐dependent	   transcription	   in	   neighboring	  astrocytes.	   In	   this	   way,	   APP	   downregulates	   astrocyte	   sterol	   production	   and	   reduces	  neuronal	  sterol	  delivery	  from	  astrocytes.	   In	  cholesterol-­‐enriched	  neurons,	   intracellular	  APP	  signaling	  also	  reduces	  cholesterol.	  This	  involves	  AICD-­‐mediated	  negative	  regulation	  of	  SREBP2	  signaling,	  presumably	  in	  cooperation	  with	  a	  different	  set	  of	  proteins	  than	  in	  the	  case	  of	  AICD	  generated	  by	  the	  α-­‐secretase	  pathway.	  
	  
Figure	  9.	  Model	  of	  APP-­regulated	  cholesterol	  metabolism.	  	  




Conclusions and Future Prospects  	  	  In	  this	  study,	  we	  investigated	  how	  DHEA-­‐FAE-­‐LDL	  is	  processed	  in	  the	  cell	  by	  comparing	  it	  to	  CE	  processing.	  DHEA-­‐FAE-­‐LDL	  uptake	  is	  antagonized	  by	  excess	  LDL,	  suggesting	  an	  LDLr	   or	   LDLr-­‐related	   uptake	   of	   DHEA-­‐FAE-­‐LDL.	  We	   also	   identified	   the	  metabolites	   of	  DHEA-­‐FAE	  after	  hydrolysis.	  While	  the	  cellular	  DHEA-­‐FAE	  level	  decreases,	  suggesting	   it	  is	   being	   processed,	   free	   DHEA	   and	   two	   metabolites,	   5α-­‐androstanedione	   and	  androstenedione,	   are	   secreted	   into	   the	  medium.	  To	  understand	  DHEA-­‐FAE	  hydrolysis,	  we	   assessed	   the	   LAL	   activity	   in	   hydrolyzing	  DHEA-­‐FAE,	   since	   LAL	   is	   the	   enzyme	   that	  hydrolyzes	   LDL-­‐borne	   CE.	   LAL	   exhibits	   modest	   activity	   in	   hydrolyzing	   DHEA-­‐FAE	  compared	   with	   CE,	   implying	   that	   there	   are	   other	   players	   involved	   in	   this	   process.	  Hormone-­‐sensitive	  lipase	  could	  be	  one	  of	  these	  players	  in	  DHEA-­‐FAE	  hydrolysis,	  which	  may	  require	  multiple	  lipase	  activities,	  and	  future	  study	  on	  this	  would	  be	  beneficial.	  	  	  	  Desmosterol	  accumulates	   in	   the	  developing	  brain	  of	  several	  species.	  We	  combined	  the	  literature	  and	  our	  own	  findings	  and	  provided	  evidence	  for	  the	  cause	  and	  consequences	  of	   desmosterol	   accumulation	   during	   the	   development	   of	   the	   mammalian	   brain.	   First,	  desmosterol	   accumulation	   could	   be	   caused	   by	   posttranscriptional	   repression	   of	  DHCR24	   by	   progesterone.	   Second,	   desmosterol	   accumulation	   may	   promote	   sterol	  secretion	   from	   astrocytes	   in	   the	   brain	   by	   activating	   LXR	   signaling,	   thereby	   increasing	  the	  ABCA1	  protein	   level.	   Third,	   desmosterol	   accumulation	   could	   serve	   to	   enhance	   the	  levels	   of	   active	   brain	   sterols	   by	   reducing	   the	   formation	   of	   inert	   sterol	   esters	   and	  secretory	   24S-­‐hydroxysterols.	   Together,	   these	   processes	   may	   assist	   in	   the	   rapid	  accumulation	  and	  distribution	  of	  sterols	  that	  are	  required	  in	  the	  developing	  brain.	   	  Cholesterol	  influences	  APP	  processing,	  and	  in	  turn	  the	  APP	  proteolytic	  products	  Aβ	  and	  AICD	  are	  known	  to	  regulate	  cholesterol	  balance.	  This	  study	  investigated	  the	  direct	  role	  of	   APP	   in	   cholesterol	   homeostasis	   by	   acute	   manipulation	   of	   APP	   and	   proteolytic	  fragment	  levels.	  We	  showed	  that	  APP	  regulates	  cholesterol	  synthesis	  and	  uptake	  via	  the	  SREBP2	   pathway,	   and	   unraveled	   the	   differential	   regulation	   via	  α-­‐	   vs.	   β-­‐processing	   of	  APP.	  While	  no	  difference	  was	  seen	   in	  APP	  C-­‐terminal	   fragments	  produced	  via	  α-­‐	  vs.	  β-­‐cleavage,	   we	   identified	   N-­‐terminal	   ectodomains	   as	   the	   new	   regulators	   of	   cholesterol	  synthesis.	   APPsα	   enhances	   and	   APPsβ	   inhibits	   cholesterol	   synthesis	   via	   the	   SREBP2	  pathway.	  We	  also	  provided	  evidence	  that	  APPsα	  promoted	  mature	  SREBP2	  stabilization	  by	   GSK3β	   inhibitory	   phosphorylation.	   To	   gain	   further	   insight	   into	   the	   mechanism	   of	  APPsα-­‐inactivating	   GSK3β,	   the	   upstream	   kinase	   activities	   in	   the	   GSK3β	   signaling	  pathways	   need	   to	   be	   analyzed.	   Additionally,	   there	  may	   be	   other	   non-­‐GSK3β signaling	  pathways	  involved	  in	  parallel.	  The	  cellular	  receptor	  for	  APP	  ectodomains	  and	  how	  they	  trigger	  the	  signaling	  pathways	  also	  need	  further	  elucidation.	  The	  role	  of	  APP	  processing	  in	   regulating	   cholesterol	   homeostasis	   is	   ubiquitous,	   based	   on	   our	   observations	   in	  astrocytic,	  hepatocytic,	   and	   fibroblastic	   cells.	   In	  APPDp	  FAD	  patient	   serum	  samples,	  we	  observed	   a	   decrease	   in	   the	   ratio	   of	   circulating	   cholesterol	   precursors	   to	   cholesterol,	  indicating	  impaired	  cholesterol	  synthesis.	  We	  proposed	  the	  possibility	  that	  the	  ratios	  of	  circulating	   cholesterol	  precursors	   to	   cholesterol	  may	   reflect	  APP	  amyloidogenesis	   and	  may	  serve	  as	  an	  early	  biomarker	  for	  AD. 
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